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Throughout Latin America, an epidemic of a kidney disease of an unknown etiology 
has been occurring since the late 1990s, and this disease is being called 
“Mesoamerican nephropathy.” Mesoamerican nephropathy predominantly affects 
male sugarcane workers. In Chichigalpa, Chinandega, Nicaragua, there is sugarcane 
plantation that is being heavily impacted by the Mesoamerican nephropathy 
epidemic, and they invited researchers from Baylor College of Medicine to 
investigate the epidemic. The prospective epidemic investigation began in 2015, and 
it is an ongoing investigation. Based on the compilation of data collected during the 
preliminary investigation, our hypothesis is that a possible zoonotic disease, such as 
hantavirus and/or Leptospira, could be causing Mesoamerican Nephropathy due to 
the large rodent population in the fields. Our specific aims were to determine the 
prevalence of hantavirus and Leptospira among the study population and to describe 
and evaluate the differences between potential risk factors for MeN. We tested for 
IgM and IgG antibodies using ELISA kits for hantavirus and Leptospira. For 
hantavirus, we tested 149 cases and 50 controls. Due to kit validation issues, we 
tested 92 controls for Leptospira IgM and IgG antibodies, and we tested 104 cases for 
Leptospira IgM antibodies and 45 cases for Leptospira IgG antibodies. We also built 
a multivariate logistic model using the purposeful model selection method to evaluate 
potential risk factors for the disease. The model was tested for goodness of fit and 
validated. We found that hantavirus had an overall prevalence of 12.1% and 
Leptospira had 27% prevalence for IgM antibodies with 1.5% for IgG antibodies. 
Hantavirus and Leptospira were not statistically found to be probable causes for the 
epidemic. The results from the multivariate model found that the use of some types of 
protective equipment and access to safe drinking water help to reduce the odds of 
disease. Having an immediate family member also increases the odds. While the 
results of this study allow us to eliminate hantavirus and Leptospira, it does not 
eliminate a possible zoonotic pathogen. Implementing the use of protective 
equipment and providing access to safe drinking water may be possible prevention 
strategies. Continued investigation is needed to determine the etiology of the 
epidemic. 
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BACKGROUND  
Literature Review  
Throughout Central America, an unexplained kidney disease epidemic has been 
occurring since the 1990s.1 The cause(s) of this kidney disease remains unknown. The disease is 
being called Mesoamerican nephropathy (MeN).1 MeN is characterized by a rapid progression of 
kidney disease that is identified when patients present for medical care with chronic kidney 
disease of unknown etiology (CKDu).1,2,3 Curiously, the commonly known renal disease risk 
factors, such as diabetes and hypertension, are not present in the individuals with MeN.1,4, 5 
Previous studies have shown that MeN can also present in cases with acute kidney injury 
(AKI).1,6-10 However, most studies investigating MeN focus on patients in the late stages of 
disease (CKDu) rather than in the earliest, acute phase (AKI).  
One of the countries highly impacted by this epidemic is Nicaragua.1,11,12 Within 
Nicaragua, MeN is disproportionately impacting sugarcane workers in Chichigalpa, 
Chinandega.1,13,14 One leading hypothesis suggests an infectious agent causing the epidemic.1 
Researchers noted the warm, tropical weather patterns for this area alongside occupational and 
environmental exposures that could be conducive to infectious disease transmission. 1 A large 
rodent population was discovered, which could harbor pathogens potentially responsible for 
causing kidney disease that the workers are exposed to in the sugarcane fields. 1 Two possible 
infectious rodent-borne pathogens are hantavirus and Leptospira.1   However, the hypothesis of 
one of these, or any other agents, as the cause of MeN has not yet been fully examined. 
Hantavirus 
 Hantavirus is a relatively recently described pathogen infecting humans. Hemorrhagic 
fever with renal syndrome (HFRS) is one of the major clinical scenarios that results from 
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hantavirus infection in humans.13-15 HFRS manifests typically through 4 clinical phases.14,16 In 
the first phase, the majority of HFRS cases experience high fevers, flulike symptoms, abdominal 
pain, and headaches accompanying the renal syndrome.14 Renal syndrome is characterized by 
elevated creatine levels and reduced renal filtration. The real danger of HFRS is the damage to 
the vascular system that occurs throughout the body, which can lead to internal hemorrhaging 
throughout the capillaries.14 When symptoms are present, antibody detection with seroconversion 
and virus isolation are the best diagnostic methods.15 IgM assays can detect antibodies to 
hantavirus in serum during the acute infection phase. Using IgM and IgG assays on paired (acute 
and convalescent) sera samples can be used to demonstrate seroconversion.15   
 Throughout the world, rodent population dynamics are strongly connected to hantavirus 
epidemics.17,18 In geographical areas highly populated with rats, there are higher numbers of 
HFRS cases.19  Rats and mice are the predominant reservoirs and carriers of hantavirus that can 
transmit the infection to humans.17 The most common mode of transmission is when infected rat 
urine or feces becomes airborne and inhaled by a human.17 For this route of transmission, these 
factors must occur: a highly dense carrier population, the carrier’s habitat must be available to 
the human, and the human needs to come in contact with the virus while it is viable outside of 
the carrier.17 Thus, breaking the link between the carrier and the human could be beneficial to 
preventing hantavirus infection. Understanding specific exposures putting people at risk in 
settings where hantavirus is known to circulate can ultimately lead to targeted prevention 
measures. 
 In recent years, the frequency of hantavirus infections is rising.17 One study conducted by 
Montoya-Ruiz, et al examined the prevalence of hantavirus in 10 nations located in Central and 
South America.20 Within the Americas, the monitoring of hantavirus is a more recent 
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development since the 1990s.20 Reports state that there are over 30 different strains of hantavirus 
within Central and South America. 20 In their research, they found an outbreak of hantavirus 
infection in humans in Panama that was most likely transmitted from rodents.20 Overall, they 
found that there is need for improved surveillance of hantavirus in Latin America.  
Leptospirosis 
 Spirochetes of the genus Leptospira cause leptospirosis.19-22 Of all zoonotic infections, 
leptospirosis is the most common in the world. 21-22 Globally, there are more than 1 million 
people infected by leptospirosis every year.22 This creates a significant global burden of disease. 
Nations with tropical and subtropical climates have the highest transmission rates of 
leptospirosis.19,21-22 As global warming continues to raise temperatures and alter weather patterns 
worldwide, the risk of Leptospira infections will greatly increase.22 In addition, tropical and 
subtropical climates are susceptible to leptospirosis epidemics following strong storm systems 
with large amounts of rain and flooding.22 
 Like Hantavirus, rodents are the main carriers of Leptospira, but other mammals can also 
carry and transmit Leptospira.22 Also similar to hantavirus, transmission of Leptospira to humans 
involves exposure to infected urine.21-22 This can occur through exposure to water and soil that 
have been contaminated with infected urine. Within endemic areas, people living in 
impoverished areas and people with occupational exposures are the most vulnerable groups for 
contracting leptospirosis.22 The occupation with the highest prevalence of leptospirosis is 
sugarcane workers.22 A study conducted in Chinandega, Nicaragua, found that almost three-fifths 
of sugarcane workers have leptospirosis.22-23 Some possibility of Leptospirosa infection 
transmission to sugarcane workers are exposure to infected rats living in the fields, aerosolization 
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of infected field soil, and contact with run-off from fields that collect in irrigation and drainage 
ditches.22-23  
 Leptospirosis manifests itself in humans in different ways.  There is typically a range of 
people experiencing mild to severe symptoms, with only a  few individuals will be asymptotic.22 
For minor illness, people typically experience a fever, headache, and myalgia, but there can be 
more negative consequences from infection.24 For instance, leptospirosis can negatively impact 
people through the kidneys by causing renal insufficiency or acute renal failure.24 This can lead 
to AKI and CKD in individuals without other risk factors for kidney disease.22 As with 
hantavirus, a common practice is to test for IgM and IgG antibodies to Leptospira in humans 
presenting with symptoms of leptospirosis.   
Numerous studies have examined leptospirosis cases in endemic nations. One example is 
a cohort study conducted in Taiwan following a flood which monitored communities to assess a 
possible relationship between CKD and leptospirosis.21 Data from that study suggest that CKD 
may result from Leptospira infection. A retrospective cohort study conducted by Daher et al in 
Brazil looked at clinical data from patients with confirmed leptospirosis.25 Of these cases, nearly 
90% presented with AKI.25 Many patients had the common symptoms of leptospirosis such as 
fever, headache, myalgia, etc. 25 Most of those patients were young adults.25 Within that 
population, they also found that individuals working as farmers had a greater risk of 
leptospirosis.25      
Public Health Significance 
The Pan American Health Organization estimates that over 50,000 individuals have died 
prematurely as a result of MeN.1,6, 26 Despite the vast number of lives this epidemic has claimed, 
the cause of MeN remains unknown. One of the primary goals of epidemiology is to determine 
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the cause(s) of disease in order to stop epidemics and to prevent more individuals from becoming 
diseased. Since most individuals with MeN do not have the expected risk factors to develop 
kidney disease, something else, possibly an infectious pathogen or pathogens, is causing MeN.1 
For this reason, improved surveillance and testing of leptospirosis and hantavirus may be 
beneficial in endemic nations experiencing CKDu epidemics. As previously mentioned, prior 
studies investigating MeN focused primarily on CKDu cases. The studies that have researched 
AKI have done so to document that AKI is a part of the early progression of MeN.6-10 Inasmuch, 
there is a need to investigate whether the AKI in the early disease process is linked to 
leptospirosis or hantavirus infection and to understand the potential occupational exposures and 
behavioral exposures associated with AKI in MeN.   
Specific Aims  
In Chichigalpa, Chinandega, Nicaragua, there are over 500 sugarcane workers with MeN 
working at ISA.1 As throughout Latin American, the cause of the MeN remains a mystery.1 In 
Chichigalpa, the sugarcane fields have a high-density population of rodents, and sugarcane 
workers spend extended periods of time within these fields, exposing them to infectious diseases 
transmitted by rodents. The epidemiology of rodent-borne diseases, such as leptospirosis and 
hantavirus, has not been described within this specific population of sugarcane workers and has 
not yet been evaluated as the cause of MeN.1    
The long-term goal of this study is to discover the cause(s) of MeN and to prevent new 
cases from occurring. The overall objective of this proposed thesis is to investigate hantavirus 
and leptospirosis as potential causes of MeN. The central hypothesis of this study is that 
hantavirus and/or leptospirosis will be more prevalent in individuals with MeN than healthy 
individuals. The central hypothesis will be objectively tested through 2 specific aims: 
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Aim 1: To determine the prevalence of hantavirus and leptospirosis among cases and 
controls through laboratory testing. 
Aim 2: To describe and evaluate the differences potential risk factors for MeN through 
statistically analyzing interview data from cases of MeN and controls 
The expected outcomes of this study are as follows: the cases will have a higher 
prevalence of antibodies to Leptospira than controls and higher prevalence of antibodies to 
hantavirus than controls. Differences in possible risk factors for MeN between cases and controls 
are also expected, with the cases having risk factors for rodent-borne pathogen transmission than 
the controls have.  The alternative, null hypothesis is that the prevalence of antibodies to 
hantavirus and leptospirosis will not be different between cases and controls. Additionally, the 
alternative, null hypothesis predicts that there will not be differences in exposures between cases 
and controls.    
METHODS 
Study Design 
This is a cross-sectional study to determine if hantavirus infection and/or leptospirosis 
may be involved with the MeN epidemic in Nicaragua. This study is being conducted as part of a 
larger investigation into the MeN epidemic entitled “Investigation into the Etiology of 
Unexplained Kidney Disease in Nicaragua” by researchers at Baylor College of Medicine in 
Houston, Texas, and Texas A&M University Health Science Center in College Station, Texas. 
Study Setting 
The study setting is a commercial sugarcane plantation, Ingenio San Antonio (ISA), in 
Chichigalpa, Chinandega, Nicaragua. The area surrounding ISA has been identified as one of the 
MeN “hotspots” in Central America as well as a possible epicenter of the MeN epidemic.27 Due 
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to this high burden of MeN, this study site is ideal for the etiologic investigation. In February 
2015, researchers initiated active surveillance for early-stage MeN disease at ISA’s large, private 
hospital, which is located on the plantation grounds. The ISA workers and their families use this 
hospital for their primary healthcare needs. Surveillance is currently ongoing.  
Study Subjects 
To be included in the study, an individual must work at ISA. Over 70% of the subjects 
live in Chichigalpa, as well. Most are under the age of 35. See table 1 for a description of the 
study population.  
Table 1: Sample Demographics 
 
  
 
 
Age 30+ 
  
  
Yes 
No 
Controls 
(N=160) 
Cases 
(N=584) 
P-value for Pearson 
Chi2 
86 
74 
235 
349 
Pr = 0.002 
  
 
Sex 
 
  
Male 
Female 
150 
13 
527 
57 
Pr = 0.489 
  
 
Smoking Status 
  No, Never 
Yes, Former 
Yes, Current 
77 
38 
41 
396 
83 
130 
Pr = <0.001 
  
  
 
 
 
 
Number of years 
worked at ISA 
  
  
  
<2 
3 to 6 years 
7 to 10 years 
>10 
24 
54 
32 
53 
136 
171 
118 
112 
Pr=0.003 
  
  
  
 
A case is defined as an individual who presented to the emergency department at the 
estate’s private hospital and was diagnosed with AKI suspected as due to MeN by the local 
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attending physician. For the overarching study, local physicians at the hospital completed case 
report forms on each case, and the hospital laboratory reported clinical laboratory findings (urine 
analysis, blood chemistry, and hematology). Common complaints were fever, nausea, vomiting, 
arthralgia, myalgia, headache, neck and back pain, weakness, and paresthesia. Furthermore, most 
cases had evidence of systemic inflammation or immune activation.1 After a case was discharged 
from the hospital, a trained study nurse would obtain informed consent into the overarching 
study prior to administering an interview about the case’s possible exposures and behaviors at 
both work and home. Cases of MeN occur throughout the year. For the purpose of this study, 
cases were selected from individuals presenting within the time frame of January 2015 – 
February 2017. 
A control is defined as an individual who works at the ISA sugarcane plantation and who 
has never been diagnosed with MeN or other type of kidney disease. Controls were recruited in 
October 2016, during the routine, annual occupational health screenings that are held before each 
harvest season. A trained study nurse obtained informed consent and administered an interview 
similar to the interview administered to infected cases. The information for cases and controls 
has been previously coded with study and sample IDs.   
Sample Size Calculation 
To calculate the sample size for Aim 1 to determine the prevalence of leptospirosis and 
hantavirus infection, the prevalence of Leptospira antibodies in a study sample was first 
calculated in a preliminary study, which is 60%.27 The formula used to calculate sample size: 
𝑛 =
𝑝(1 − 𝑝)(𝑧𝑎/2)
2
𝑑2
 
For this formula, p is 0.60, 𝑧𝑎/2 is 1.96 for 95% confidence intervals, and d, the absolute error, 
was 6.8%. This gave a sample size of 199.39, which was rounded up to 200 for the total sample 
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size. The sample size calculation was confirmed through OpenEpi.28 For the ELISA assays, a 
sample of 100 controls and 100 cases were drawn for the acute sample testing only. An 
additional sample of 75 cases were added to test seroconversion using paired (acute and 
convalescent) samples. For aim 2, all individuals on whom interview data was collected will be 
used in analysis. The entire universe of data will be analyzed, and no sample will be drawn. For 
this reason, a sample size was not calculated. Data include case report forms on 610 case patients 
and a subset of interview data on 244 case patients and 163 controls. These data will be included 
in the statistical analysis portion.  
Data Collection 
 As part of the larger investigation into the etiology of MeN, the cases and controls are 
currently being tested for evidence of exposure to hantavirus and Leptospira via enzyme-linked 
immunosorbent assay (ELISA) to detect antibodies (IgM and IgG). For both hantavirus and 
Leptospira infections, use of ELISA is common practice to detect antibodies. The ELISA kits for 
hantavirus are Focus Diagnotistics IgM, and IgG DxSelectTM (Langenhagen-Hannover, 
Germany). The ELISA assay kits for leptospirosis are Virion-Serion (Wurzburg, Germany) 
classic Leptospira IgG and IgM tests. The ELISA assays are performed following the 
instructions for each kit. The specimens to be tested are selected using simple random sampling 
from the sera stored in Houston. The samples are brought to room temperature gradually by 
either thawing in the refrigerator overnight or thawing on the lab bench the day of the ELISA 
assay. The recommended number of positive controls, negative controls, cut offs, and blanks are 
used for each plate run as specified by the kit instructions; all procedures were carried out 
according to kit specifications (see Appendix I and II). Serum samples are stored in -80°C 
freezers in Houston. 
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During the overarching study, any worker presenting with AKI to the ISA hospital were 
asked for consent and had a serum sample taken and stored. These individuals were monitored 
and followed up with trained cases professionals to see if they would develop MeN. 
Convalescent samples were taken after an individual was classified as a case. The sera samples 
used for this study are from individuals who did develop MeN. All workers undergo 
occupational health screenings prior to employment each harvesting season.1 The serum samples 
from controls in this analysis were drawn during the October 2016 screenings, which is when 
control workers were enrolled in the study and interviewed about potential exposures of interest, 
including demographics, medical history, and possible risk factors (environmental, occupational, 
behavioral). For example, some of the information gathered includes drinking water sources, 
handwashing practices, exposure to rodents, type of occupation at ISA, etc. 
For the cases, the serum collected during hospital admission at the onset of acute kidney 
disease were analyzed. In addition, approximately ≥3 months following discharge from the 
hospital, convalescent samples were also drawn from cases. For 75 of the cases, paired acute and 
convalescent samples were analyzed to evaluate seroconversion from IgM (acute) to IgG 
(convalescent) antibodies for hantavirus and Leptospira.  
Data Analysis 
The statistical analysis portion of the proposed thesis will be broken into two main parts. 
Aim 1: 
a) Prevalence of Antibodies  
The results from the ELISA assays for both hantavirus and leptospirosis will be analyzed 
separately, for prevalence ratios between cases and controls. The dependent variable is acute 
kidney disease (case status). For each infection, the main independent variable is positive 
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serology. A serum sample exhibiting a seropositive test result is defined as ELISA test which is 
positive for either IgM or IgG, according to manufacturer protocol, indicating a current, recent, 
or past antibody response to pathogen. For a subset of cases, the acute seroconversion rate 
between IgM and IgG for hantavirus and Leptospira infections will be calculated for the paired 
acute and convalescent samples. Seroconversion is defined as:  
1. having IgM negative acute specimen with IgM or IgG positive convalescent specimen 
or 
2. having IgM positive acute specimen with IgG positive convalescent specimen. 
 
b) Descriptive Statistics 
Using data from the case reports and interviews, the prevalence of hantavirus and 
leptospirosis will be calculated for each variable individually: sex, age, residence, drug use, 
the number of years working at the sugarcane field, type of position at the sugarcane farm, 
working in contact with soil, and working in contact with water. Each variable will first be 
tested against Pearson’s Chi Test or Fischer’s Exact test if there are too few observations. 
Then, for the significant variables, the prevalence ratios with confidence intervals will be 
calculated for all of these, using Poisson regression to estimate. In addition, statistical 
assessment for potential confounders will be performed.  This descriptive analysis will be 
conducted separately for Leptospira and hantavirus infection, each using both seropositive 
and seroconverted outcomes. 
Aim 2: Logistic Regression: 
In order to evaluate the impact of hantavirus or Leptospira infection positivity and other 
potential exposures in MeN, data from the interviews will also be analyzed alongside the 
laboratory testing results to build a logistical model to evaluate each characteristic as a potential 
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risk factor, comparing patients with MeN to control workers. The odds ratios with confidence 
intervals for the variables selected in the multivariate model will be reported. See Table 2 for a 
list of variables to be tested for the model. The response variable is MeN case status. A subset of 
the dataset with complete interview information will be used for model building. The purposeful 
model selection steps as defined by Hosmer, Lemeshow, and Sturdivant will be used for model 
selection.29 
Table 2: Variables to be included in model selection 
Sex Age Residence location Drug use 
Number of years 
working at ISA 
Type of position at 
ISA 
Contact with soil 
while working 
Contact with water 
while working 
Have seen rodents in 
the fields at work 
Have seen rodents at 
home 
Hand washing 
practices at work and 
home 
Drinking water 
sources at work and 
home 
Protective gear use Own pets Gardening as a hobby Medical history 
Family history of 
Mesoamerican 
Nephropathy 
   
 
First, a univariable analysis will be conducted individually for each potential variable 
using the likelihood ratio (LR) test. Categorical variables with multiple levels will be tested 
using the LR test followed by a contingency table analysis to confirm the decision to keep or 
drop the variable. All variables that have a p-value less than 0.25 will be used to run one large 
multivariate logistical model. The LR test will be used to determine which variables to exclude 
and to include using a p-value of 0.05 or less. Each excluded variable will be individually added 
to the model and tested again using the LR test to see if it is a significant variable. If it is 
significant, a LR test between the model with the added variable compared to the null model will 
determine if the variable will be included in the next step of model building. Retained variables 
will form the preliminary main effects model. Prior to moving to the next step of the purposeful 
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model selection, the variables that were excluded during the univariate analysis will be added to 
the model individually and then tested using the LR test. If they are significant, they will be 
added to the model. 
 For all the continuous variables in the model, linearity will be tested using a Lowess 
smooth plot. Variables that demonstrate linearity will be included in the model. The variables 
that break linearity will be transformed through fractional polynomials and cubic spline functions 
to see if the linearity is fixed.  The models generated will then be tested against the original 
preliminary effects model. If the LR test is significant, the transformed variable will be included 
in the model. 
 Before accepting the final model, any biologically plausible interactions will be tested. 
Each biologically plausible interaction term will be tested individually in the model. The LR test 
will be kept in the model if the results are significant. The final preliminary model will be 
complete, and the AIC will be tested.  
Prior to accepting the model, two methods will be used to assess the goodness of fit: The 
Pearson χ2 Goodness of Fit test and Hosmer-Lemeshow Test using 10 groups. Comparison of the 
AICs, log likelihoods, LR test, R2, Pearson χ2 Goodness of fit, and the Hosmer-Lemeshow test 
will be used to assess the model. Finally, the model will be also be validated in STATA. The 
dataset will be run through STATA’s stepwise model building program, and the generated model 
will be compared to the model built through the purposeful selection. 
After the final model is built, the data will then be interpreted through the model. The odd 
ratios with confidence intervals of each variable included in the final model will be assessed. 
This information will be used to guide future steps in the investigation of MeN.  
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Human Subjects  
 The IRB approval for this study is from the Baylor College of Medicine. The Principal 
Investigator Dr. Kristy Murray granted permission to analyze data and specimens. The study was 
also reviewed and approved by the ethics boards at the Nicaragua Ministry of Health and by the 
Medical Directors of the Hospital Alfredo Chamorro Pellas and Gerencia de Salud Ocupacional 
at ISA. Participants who were interviewed gave consent for the use of the interview data and 
samples. Data from individuals who were not interviewed were exempted from consent by all 
ethics boards. All data from participants used in the study has been deidentified to protect 
participants. The thesis proposal was submitted to iRIS of the UTHealth system on August 13, 
2018, for approval, and it was approved on September 6, 2018. 
RESULTS 
Specific Aim 1: ELISA Lab Results for Hantavirus and Leptospira 
 A total of 199 patients were tested for IgG and IgM antibodies to hantavirus (149 cases 
and 50 controls). A total of 90 paired acute and convalescent sera samples from cases were tested 
for seroconversion in antibodies to hantavirus. A total of 196 patients were tested for IgM 
antibodies to Leptospira (104 cases and 92 controls), and a total of 137 patients were tested for 
IgG antibodies to Leptospira (92 controls and 45 cases).  The results of the ELISA Hantavirus 
IgM and IgG are displayed below in Table 3.  
The prevalence of hantavirus IgG antibodies is 9.6% among all tested samples with 6.7% 
of cases testing positive and 18% of controls testing positive. The odds of testing negative for 
IgG among cases were more than 3 times as likely than among controls. The test of homogeneity 
between cases and controls was significant for hantavirus IgG results, but not for hantavirus IgM 
results.  For IgM hantavirus antibodies, only 3.4% of the cases tested positive with none of the 
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controls testing positive. Of the 90 paired acute and convalescent samples, there was 6.67% 
(n=6) seroconversion rate.  
Table 3:  ELISA Results 
ELISA Results 
  Negative Positive Total 
Hantavirus IgG   
50 
149 
Control 41 (82%) 9 (18%) 
Case 139 (93%) 10 (7%) 
Total 180 (90%) 19 (10%) 199 
  
Test of Homogeneity P-
value =0.191  
Hantavirus IgM    
Control  50 (100%) 0 (0%) 50 
Case 144 (97%) 5 (3%) 149 
Total 194 (97.5%) 5 (2.5%) 199 
  
Test of Homogeneity P-
value=0.019  
Leptospira IgG    
Control 90 (98%) 2 (2%) 92 
Case 45 (100%) 0 (0%) 45 
Total 135 (98.5%) 2 (1.5%) 137 
 
 
  
Test of Homogeneity P-
value =0.3208 
 
Leptospira IgM Negative Positive Total 
Control 63 (68%) 29 (32%) 92 
Cases 80 (77%) 24 (23%) 104 
Total 143 (73%) 53 (27%) 196 
  
Test of homogeneity p-
value= 0.1852  
 
The possible exposure factors were each tested against the positive hantavirus ELISA 
results for IgM and IgG. None of them were significant, except for three variables. The first one 
was the difference between cases and controls testing positive for hantavirus IgG antibodies. 
More controls than cases tested positive for IgG antibodies (PR 0.373 [CI 0.160-0.867]; 
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p=0.032). The second is the IgM result for individuals who have contact with rain water while 
working. Individuals testing positive for hantavirus were more than 10 times as likely to have 
contact with rain water than those who did not (PR 10.6 [1.64-68.8]; p=0.018). The third and last 
significant result was for an IgG hantavirus positive antibody result and for those who currently 
drink alcohol and/or used to drink alcohol. For the individuals who have ever drank alcohol, they 
were significantly less likely to test positive for IgG hantavirus antibodies than those who have 
never drank alcohol (PR 0.108 [0.014-0.860]; p=0.035).  
Specific Aim 2: MeN Multivariate Model 
 The results from the univariate analysis are displayed in Table 4. See Appendix VI for the 
results of all the variables examined. A total of 107 variables were examined prior to being 
analyzed to build a statistical model. The final model is log[casecontrol] = -1.958[work involves 
contact with the field] - 1.343[handwash using clean municipal water]  + 2.567[drank from a 
particular well in the field] – 2.597[drinks from wells in general] – 0.949[ uses protective gloves] 
+ 1.38[wears protective long sleeves] + 1.402[has an immediate family member with MeN] – 
0.793[has smoked] -1.132[has had moonshine] + 1.474[sees rats in the field while working] – 
1.94[works in the field in general] – 1.472 [wears protective eye glasses] + 1.01}. Table 5 
displays the results of the final statistical model predicting MeN. The model passed the goodness 
of fit testing as well as the validation step.   
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Table 4: Univariate Analysis with Whole Dataset 
Variable 
Obs 
Control 
(n/N) 
Cases 
(n/N) OR 
Std 
Error 
Z 
P-Value 
Confidence 
 Intervals 
Sex (Males) 
747 
150/163 
(92%) 
527/584 
(90%) 1.248 0.401 0.690 0.490 0.665 2.341 
AGE CATEGORIES  
  
      
 
Above the age of 30 
744 
 
86/160 
(23%) 
 
235/584 
(40%) 0.579 0.104 
-
3.040 0.002 0.407 0.824 
 
Above the age of 25 
744 
 
119/160 
(74%) 
 
389/584 
(66.7%) 0.687 0.138 
-
1.860 0.062 0.463 1.020 
 
Above the age of 35 
744 
 
45/160 
(28%) 
 
132/584 
(23%) 0.746 0.151 
-
1.450 0.147 0.503 1.108 
Resides in Chichigalpa 
739 
 
100/159 
(63%) 
 
377/580 
(65%) 1.096 0.204 0.490 0.623 0.761 1.577 
 
DRUG USE 721 
   
      
Yes, former 
 
12/161 
(7.5%) 
28/560 
(5%) 
 
0.661 0.237 -1.16 0.248 0.328 1.333 
Yes, current 
 
28/560 
(5%) 
17/560 
(3%) 
1.606 1.017 0.75 0.454 0.464 5.557 
 
Have Ever Used Drugs  
15/161 
(9%) 
45/560 
(8%) 0.850 0.266 
-
0.520 0.604 0.461 1.569 
 
TOTAL YEARS 
WORKED AT ISA 700 
  
      
 
<2 years  
24/163 
(15%) 
136/537 
(25%)       
3-10 years 
 
86/163 
(53%) 
289/537 
(54%) 0.593 0.150 -2.06 0.039 0.361 0.974 
>10 years 
 
53/163 
(33%) 
112/537 
(21%) 0.373 0.103 -3.56 <0.001 0.217 0.642 
OCCUPATION  
  
      
 
Workings in 
carrying/hauling 407 
5/163 
(3%) 
18/244 
(7%) 
2.517 1.299 1.790 0.074 0.915 6.920 
 
Works as General 
Harvester 407 
27/163 
(17%) 
15/244 
(6%) 
0.330 0.112 
-
3.260 0.001 0.170 0.642 
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Variable Obs 
Control 
(n/N) 
Cases 
(n/N) OR 
Std 
Error 
P-Value Confidence 
 Intervals 
OCCUPATION 
CONTINUED  
  
     
 
Works in planting 407 
39/163 
(24%) 
43/244 
(18%) 0.680 0.169 0.121 0.418 1.108 
 
Pest Control 407 
5/163 
(3%) 
15/244 
(6%) 3.389 3.729 0.267 0.392 29.278 
Weed Control 
407 
2/163 
(1%) 
18/244 
(7%) 6.411 4.824 0.014 1.467 28.019 
 
Works in 
Irrigation/Drainage 407 
29/163 
(18%) 
42/244 
(17%) 
0.961 0.255 0.880 0.571 1.618 
Auto mechanic 
407 
15/163 
(9%) 
8/244 
(3%) 0.334 0.151 0.015 0.138 0.808 
occup_fabrica 
407 
2/163 
(1%) 
6/244 
(2.5%) 2.029 1.670 0.390 0.405 10.181 
Work involves contact 
with the field 370 
115/163 
(71%) 
89/207 
(43%) 0.315 0.07 <0.001 0.204 0.486 
Works with soil 
175 
103/163 
(63%) 
10/12 
(83%) 2.913 2.305 0.177 0.617 13.739 
Works with dry soil 
239 
68/163 
(42%) 
5/76 
(7%) 0.098 0.048 < 0.001 0.038 0.257 
Works with wet soil 
239 
71/163 
(44%) 
4/76 
(5%) 0.072 0.039 < 0.001 0.025 0.206 
Works with soil in the 
field 239 
69/163 
(42%) 
7/76 
(9%) 0.138 0.059 < 0.001 0.060 0.319 
RODENT  EXPOSURE 
IN HOUSE  
  
     
Sees rats in house 
202 
116/148 
(78%) 
43/54 
(80%) 1.078 0.423 0.848 0.500 2.327 
Sees rat feces in house 
184 
60/130 
(46%) 
18/54 
(33%) 0.583 0.197 0.111 0.301 1.132 
Sees rats in house every 
day 202 
19/148 
(13%) 
15/54 
(28%) 2.611 1.020 0.014 1.214 5.617 
Sees rats in house 
frequently 196 
66/147 
(45%) 
18/49 
(37%) 
0.713 0.242 0.318 0.366 1.386 
HANDWASH 
PRACTICES  
  
     
Handwashes hands with 
water from house 407 
120/163 
(74%) 
161/244 
(66%) 0.695 0.155 0.103 0.449 1.077 
Handwashes with clean 
municipal water 407 
27/163 
(17%)  
8/244 
(3%) 0.171 0.071 0.000 0.075 0.386 
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Variable Obs 
Control 
(n/N) 
Cases 
(n/N) 
OR P-Value 
Confidence 
 Intervals 
HANDWASH 
PRACTICES   
  
    
Handwash with from 
municipal truck water 407 
7/163 
(4%) 
19/244 
(8%) 1.882 0.164 0.773 4.584 
Handwashes with ditch 
water 407 
4/163 
(2.5%) 
12/244 
(5%) 2.056 0.219 0.651 6.490 
Handwashes with water 
from drainage tube 407 
1/163 
(0.6%) 
16/244 
(7%) 11.368 0.019 1.493 86.586 
Handwashes with well 
water 407 
5/163 
(3%) 
13/244 
(5%) 1.778 0.283 0.622 5.087 
Always washes hands 
before eating 407 
138/163 
(85%) 
182/244 
(75%) 0.532 0.016 0.318 0.889 
Usually washes hands 
before eating 407 
17/163 
(10%) 
30/244 
(12%) 1.204 0.564 0.641 2.263 
Rarely washes hands 
before eating 407 
4/163 
(2.5%) 
12/244 
(5%) 2.056 0.219 0.651 6.490 
Never washes hands 
before eating 407 
4/163 
(2.5%) 
12/244 
(5%) 2.056 0.219 0.651 6.490 
DRINKING WATER 
SOURCE  
  
    
Drink from clean 
municipal water 407 
35/163 
(21%) 
11/244 
(5%) 0.173 0.000 0.085 0.352 
Drink from potable water 
truck 407 
9/163 
(6%) 
11/244 
(5%) 0.808 0.644 0.327 1.995 
Drink from a particular 
well in ISA’s field 407 
7/163 
(4%) 
22/244 
(9%) 2.208 0.076 0.921 5.297 
Drink from water in a 
ditch 407 
1/163 
(0.6%) 
6/244 
(2%) 4.084 0.195 0.487 34.243 
Drink from drainage pipe 
407 
1/163 
(0.6%) 
9/244 
(4%) 6.204 0.085 0.778 49.446 
Drink from drainage tube 
407 
2/163 
(1%) 
15/244 
(6%) 5.273 0.029 1.189 23.376 
USE OF PROTECTIVE 
EQUIPMENT  
  
    
Wears gloves 
376 
126/142 
(89%) 
157/234 
(67%) 0.259 < 0.001 0.144 0.466 
Wears protective eye 
glasses 378 
98/124 
(79%) 
84/236 
(36%) 0.248 < 0.001 0.159 0.387 
Wears mask over mouth 
373 
64/140 
(46%) 
49/233 
(21%) 0.316 < 0.001 0.200 0.500 
Wears mask over mouth 
and nose 372 
40/140 
(29%) 
35/232 
(15%) 0.444 0.002 0.266 0.742 
Wears long sleeves 
379 
113/141 
(80%) 
228/238 
(96%)  5.650 < 0.001 2.652 12.037 
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Variable Obs 
Control 
(n/N) 
Cases 
(n/N) 
OR P-Value 
Confidence 
 Intervals 
 
Wears boots 
380 
139/141 
(99%) 
236/239 
(99%) 1.132 0.893 0.187 6.857 
FAMILY HISTORY OF 
MeN  
  
    
Family member with 
MeN 371 
48/141 
(34%) 
140/230 
(61%) 3.014 < 0.001 1.946 4.668 
Immediate family 
member with MeN 
(parent or sibling) 371 
32/141 
(23%) 
119/141 
(84%) 
3.652 < 0.001 2.279 5.851 
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Table 5: Prediction Model for MeN 
Case Control Odds Ratio Std. Err. P>z 
[95% 
Conf. 
Interval] 
OCCUPATION BASED      
Work involves contact 
with field 
0.141 0.053 <.001 0.067 0.296 
Sees rats in the field 
while working 
4.368 2.038 0.002 1.751 10.899 
Works as a general 
harvester 
0.303 0.168 0.032 0.102 0.900 
WATER SOURCES 
Handwashing with clean 
municipal water sources 
0.261 0.157 0.026 0.080 0.850 
Drinking from a 
particular well in the 
field 
13.027 9.829 0.001 2.969 57.158 
Drinking water from 
well water in general 
0.074 0.037 <0.001 0.028 0.199 
  
USE OF PROTECTIVE 
EQUIPMENT/GEAR 
       
Wear gloves        
 0.387 0.164 0.025 0.169 0.889 
Wear protective eye 
glasses 
      
 0.229 0.092 <0.001 0.105 0.503 
Wear long sleeves        
 3.961 2.103 0.010 1.399 11.211 
Family history of CKD 
(sibling or parent) 
4.063 1.472 <0.001 1.998 8.264 
History of smoking 0.452 0.157 0.023 0.229 0.895 
History of drinking 
moonshine 
0.323 0.165 0.027 0.119 0.878 
_cons 2.745 2.124 0.192 0.602 12.508 
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DISCUSSION 
The results from the ELISAs do not support the hypothesis that hantavirus is causing 
MeN. The prevalence of testing positive to hantavirus IgG antibodies signaling a possible 
previous infection is low with an 18% prevalence among controls and 6.7% among cases. The 
significant result of the homogeneity test suggests that cases may be less likely to have had a 
hantavirus infection in the past than the controls. The POR of testing positive for IgG antibodies 
to hantavirus for cases was 0.373 against controls which also supports that cases are less likely to 
have had hantavirus in the past.  However, only 3.4% of cases have IgM antibodies to the 
hantavirus with none of the controls testing positive for IgM antibodies to the hantavirus. While 
there was a significant POR for those who work with rain water and testing positive for 
hantavirus IgM antibodies, the confidence interval was very broad. Overall, the IgM and IgG 
ELISA results do not support further investigation into hantavirus as a potential causative agent 
for MeN in Nicaragua.  
The univariate analysis results suggest numerous risk factors for MeN as well as some of 
confounding factors. For instance, age is found to be highly significant within the dataset. 
Individuals younger than 30 appear to have nearly 50% greater odds of suffering MeN than those 
30 or older than 30. However, most of the workers are 30 years of age or younger, which 
potentially skews the result. Another example of this is the total number of years worked at ISA, 
which suggests the more years worked at ISA as being protective against MeN. However, the 
majority of the workers are young, seasonal workers with less totaled years accrued at ISA, and 
this could skew the results as well. 
The data also suggest that the type of position that the study population work at ISA 
impact their risk of MeN. For the individuals working with weed control, their risk of MeN is 
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greater than 6 times greater than other positions. Another protective factor against MeN was for 
individuals that worked as automotive mechanics as opposed to workers who worked in other 
locations. Working as an automotive mechanic most likely has very different occupational 
exposures as compared to those working in the fields, and it is very possible that they are not 
exposed to the risk factor(s) that increase the likelihood of a person developing MeN.  In our 
analysis, the individuals with positions for the harvest or dealing with soil had significantly less 
risk for developing MeN. However, this relationship is unclear, since MeN has long been 
identified as a disease of agricultural field workers. While the variables dealing specifically for 
working with soil had too few observations to be examined later in the model building portion, 
there were enough data points to include a joint variable for working with soil or water in the 
model building step.  
Another significant risk factor was exposure to rodents at home or during work. There 
were not enough data on individuals seeing rats at home to be examined in the model building 
step. However, the univariate analysis found that those seeing rats within the home daily had 
significantly higher odds of developing MeN than those who did not. Furthermore, individuals 
who saw rats in the field were 3.615 times more likely to have MeN than those who did not. 
There was enough data on seeing rats in the field to be included in the model building process, 
and it was included in the final model as displayed in Table #. The significance of being exposed 
to rats does support the hypothesis that a rodent-borne agent could be a causative agent of the 
MeN epidemic. since workers who reported encountering rodents i8n the field were more likely 
to be MeN case patients. 
Water exposures were also found to be significantly associated with disease. For instance, 
handwashing using fountain water was highly protective, and handwashing with drainage tube 
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water drastically increased the odds of the MeN. Similarly, drinking water from the fountain 
significantly protected against MeN, and drinking water from the drainage pipe in the field 
severely increased the odds of MeN. The type of water exposures for individuals also played a 
significant role in the final predicting model as well. Unclean water is a known risk factor for 
many diseases due to containing infectious pathogens, including Leptospira, and harmful 
chemicals. The unsafe water exposures support an environment exposure contributing to and/or 
causing the MeN epidemic. When examining our findings about a potential role of drinking 
water source in conjunction with the added risk for MeN associated with exposure to rats, these 
data support to the hypothesis of Leptospira or a different zoonotic disease being a possible 
causative agent of MeN. 
In both the univariate analysis and predictive model, the use of protective personal 
equipment was mostly found to be protective against MeN. In particular, the use of gloves, 
protective eye glasses, face mask, and nose protective equipment all significantly reduce the 
odds of MeN. It is possible that these types of personal protective equipment may help to reduce 
or prevent exposure(s) that lead to the development of MeN, such as by interrupting the 
transmission route of a pathogen or other agent. Interestingly, wearing long sleeves was found to 
increase the odds of MeN in both the univariate analysis and the final model. This does warrant 
further investigation as it could potentially suggest that heat exhaustion may be a contributing 
factor or possibly exacerbate the condition of MeN. 
Lastly, having a family member with MeN was found to increase the odds of an 
individual having MeN in both the univariate analysis and the predictive model. It is important to 
note that the cases do not have any of the risk factors to develop kidney at a young age, but it is 
possible that there is a genetic component that make individuals more susceptible to developing 
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MeN. It is also possible that the family members work together or within the same area at ISA, 
which would mean that they potentially have the same occupational exposures.  
The predictive logistic model results mostly agreed with the univariate results, but there 
were a few differences in the predictive model. Curiously, drinking well water in the field was 
found to significantly increase the odds of MeN, but drinking well water at home or work was 
found to be protective. This does merit further investigation as it could suggest that there is a 
specific exposure that the well in the field contains that the other wells do not contain. The 
confidence interval was bit broad for the variable which a larger data sample may be able to 
address. Within the model, the factors of being a fieldworker, using fountain water to wash one’s 
hands, drinking well water at home and work (but not in the field), history of smoking, and 
drinking local moonshine/lija were all found to reduce the odds of MeN. The factors of seeing 
rats in the field, drinking from a well in the field, wearing long sleeves, and having a family 
member with MeN increased the odds of MeN among cases and controls.  
When examining the logistic predictive model in Table 5, the model fits well given the 
constraints from the dataset. Most of the confidence intervals were narrow, except for the 
variables representing the well in the field, wearing sleeves, having a family member with MeN, 
and seeing rats in the field. These all had increased odds ratios with significant p-values, but the 
confidence intervals were not narrow. Due to working with a smaller dataset, these variables do 
necessitate further investigation with more data.  
Despite the valuable information gleaned from this analysis, there are a few weaknesses. 
Since we analyzed data and biologic specimens that had already been collected, we were only 
able to analyze what was available. Not all individuals with MeN completed interviews, and 
some workers in this study declined to answer some questions during the interview, which means 
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we did not have complete information for all individuals for all variables of interest. For the 
multivariate analysis, in particular, we were limited to analyzing a subset of individuals with 
more complete dataset. The data subset had a total of 407 observations with some missing values 
for variables. Most of the variables were able to be included in the model building process, but 
there were a few variables that were excluded due to having too many missing observations. 
However, the univariate analysis and the statistical model still provide valuable information for 
future studies. In addition, statistical power was met with the sample sizes for the ELISAs, and 
the results help to guide future studies to investigate other possible infectious agents. A 
prospective case control study in the future would be highly beneficial to further investigate the 
MeN epidemic in Nicaragua, as well as define specific opportunities to interrupt transmission of 
hantavirus and Leptospira. 
CONCLUSION 
We found a very low level of exposure to hantavirus in this agriculture worker population 
in Nicaragua. We also found a low prevalence of Leptospira among cases and controls. While 
these results do not support hantavirus or Leptospira as sources of the MeN epidemic, the data 
do not eliminate a different infectious pathogen as a possible source of MeN. The association 
between seeing rats in the field and MeN do suggest a possible zoonotic disease causing MeN, 
and the results of this study support eliminating Leptospira. From the ELISA results, it may be 
useful for the local health departments to have routine testing and treatment available for 
Leptospira. Other useful applications of the results of this study would be explore any factors 
that put the agricultural workers at risk for exposure to hantavirus. Since we found controls in 
this study had more often been exposed to hantavirus, there may be specific high risk groups for 
that disease that could warrant investigation for future preventive measures. 
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We evaluated potential risk factors for MeN. We found an the association between 
several important environmental exposures and MeN, since individuals with MeN working at 
ISA had more frequent exposures to potential environmental and occupational risk factors than 
their healthy worker counterparts. We also discovered that several factors seemed to protect 
against MeN and could lead to possible intervention strategies.  Namely, the provision of safe 
drinking water and use of PPE could reduce the occurence MeN in this population. Given that 
risk factors for MeN identified herein overlap with known risk factors for infectious disease, 
particularly hantavirus and Leptospira, our data do support the hypothesis of an infectious agent 
or an environmental agent as possible contributing factors to MeN within this study population.  
Our findings contribute to a deeper understanding of the environmental exposures for the 
sugarcane workers, and continued investigations into possible infectious agents contributing to 
the MeN epidemic are needed. 
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Appendix II: Leptospira ELISA Kit Instructions 
SERION ELISA classic Leptospira IgG/IgM 
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SERION ELISA classic Leptospira IgG/IgM 
 
ENZYME IMMUNOASSAY FOR DETECTION OF HUMAN ANTIBODIES (IGG/IGM) 
 For sale in the U.S. for Research Use Only. Not for use in diagnodtic procedures.  
 
IgG-Kit (quantitative) order number: ESR125G 
IgM-Kit (quantitative) order number: ESR125M 
 
Tests evaluated: Dade Behring BEP ® III / BEP ® 2000, DSX, manually 
 
 
1. INTENDED USE 
 
SERION ELISA CLASSIC LEPTOSPIRA IGG/IGM ARE QUANTITATIVE UND 
QUALITATIVE TESTS FOR DETECTION OF GENUS-SPECIFIC HUMAN 
ANTIBODIES AGAINST LEPTOSPIRA IN SERUM OR PLASMA. FOR SALE IN THE 
U.S. FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
 
 
2. BACKGROUND 
LEPTOSPIRES ARE SPIRAL-SHAPED, GRAM-NEGATIVE, OBLIGATE AEROBIC 
SPIROCHETES WITH INTERNAL FLAGELLA. THE GENUS IS DIVIDED INTO TWO 
SPECIES, THE PATHOGENIC LEPTOSPIRA INTERROGANS AND THE FREE-
LIVING NONPATHOGENIC LEPTOSPIRA BIFLEXA. LEPTOSPIRA INTERROGANS 
HAS ABOUT 200 DIFFERENT SEROVARS BASED ON THE VARIABILITY OF 
SURFACE ANTIGENS. LEPTOSPIRES AFFECT MAMMALS (WILD AND 
DOMESTIC ANIMALS), REPTILES AND AMPHIBIANS; THEY MAY BE SHED IN 
THE URINE LIFELONG. RATS AND OTHER RODENTS ARE PRIMARY 
RESERVOIRS FOR HUMAN INFECTION. INFECTION IS TRANSMITTED BY 
URINE-CONTAMINATED SOIL OR WATER, RAT BITES OR ANIMAL TISSUE. 
ESPECIALLY OCCUPATIONAL GROUPS LIKE AGRICULTURISTS, PLUMBERS, 
MINE WORKERS, FISHERMEN AND MEAT- INDUSTRY WORKERS ARE AT 
GREAT RISK OF EXPOSURE. 
 
MUCOSA AND SKIN LESIONS ARE THE MOST LIKELY SITES OF ENTRY FOR 
LEPTOSPIRES (FIG. 1). BACTERIA MAINLY PROLIFERATE IN THE CENTRAL 
NERVOUS SYSTEM, KIDNEYS AND LIVER. 
 
 
Figure 1. 
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THE IMMUNE SYSTEM REMOVES ORGANISMS FROM BLOOD AND ORGANS 
WITHIN 4-7 DAYS BY COMPLEMENT AND HUMORAL IMMUNITY. CELL-
MEDIATED IMMUNITY DOES NOT APPEAR TO BE IMPORTANT. LEPTOSPIRES 
WITHIN THE CONVOLUTED TUBULES OF THE KIDNEYS MAY SURVIVE DUE 
TO THE INEFFICIENCY OF THE IMMUNE SYSTEM, THE COMPLEMENT SYSTEM 
IN PARTICULAR. FOR THIS REASON INFECTIOUS LEPTOSPIRES ARE SHED IN 
URINE. 
 
MICRO-AGGLUTINATION TESTS, ELISAS AND INDIRECT FLUORESCENCE-
ANTIBODY TESTS ARE MOST FREQUENTLY USED FOR SERODIAGNOSIS. 
 
 
3. SERION ELISA classic - TEST PRINCIPLE 
 
Microtest plates are coated with antigens. This constitutes the solid phase. Sample is added to the 
plates and any antibodies specific for the antigen present will bind to the solid phase. After removal of 
unbound material, anti-human IgG, IgA or IgM conjugated to an enzyme (alkaline phosphatase) is 
allowed to react with the immune complex. After removal of excess conjugate by washing, an 
appropriate substrate (para-nitrophenylphosphate) is added, with which the conjugated enzyme 
reacts producing a colored derivative of the substrate. The color intensity is proportional to the level 
of specific antibody bound and can be quantified photometrically. 
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4. COMPONENTS OF THE KIT 
 
Test components amount / 
volume 
Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96), 
1 frame 
the coating material is inactivated 
12 
Standard serum (ready-to-use) 
Human serum in phosphate buffer with protein; negative for anti-HIV-Ab, anti-HBs-Ag 
(Hepatitis B-Virus-surface antigen) and anti-HCV-Ab; preservative: < 0.1 % sodium azide 
coloring: Amaranth O 
2 x 2 ml 
Negative control serum (ready-to-use) 
Human serum in phosphate buffer with protein; negative for anti-HIV, anti-HBs (Hepatitis B- 
Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide 
coloring: Lissamin green V 
2 ml 
Anti-human-IgG-, IgA-, IgM-conjugate (ready-to-use) 
Anti-human-IgG, -IgA, -IgM from goat (polyclonal), conjugated to alkaline phosphatase, 
stabilized with protein stabilization solution 
preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane 
13 ml 
Washing solution concentrate (sufficient for 1 litre) 
Sodium chloride solution with Tween 20, 30 mM Tris 
preservative: < 0.1 % sodium azide 
33.3 ml 
Dilution buffer 
Phosphate buffer with protein and Tween 20; 
preservative: < 0.1 % sodium azide 
0.01 g/l Bromphenol blue sodium salt 
2 x 50 ml 
Stopping solution 
1.2 N sodium hydroxide 
15 ml 
Substrate (ready-to-use) 
Para-nitrophenylphosphate, solvent free buffer 
preservative: < 0.1 % sodium azide 
(Substrate in unopened bottle may have a slightly yellow color. This does not reduce the 
quality of the product!) 
13 ml 
Quality control certificate with standard curve and evaluation table 
(quantification of antibodies in IU/ml or U/ml) 
1 
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5. MATERIAL REQUIRED BUT NOT SUPPLIED 
 
- common laboratory equipment 
- for the IgM-ELISA: SERION Rf-Absorbent (Order no. Z200/20ml) 
- photometer for microtiter plates with filter, wavelength 405 nm, recommended 
reference wavelength 620 nm - 690 nm (e.g. 650 nm) 
- incubator 37°C 
- moist chamber 
- distilled water 
 
 
6. STORAGE AND STABILITY 
 
Reagent Storage Stability 
microtiter strips 
(antigen) 
after opening at 2-8°C in closed aluminum bag with 
desiccant 
 
Strips which are not used must be stored in the press-seal bag 
of aluminum compound foil under dry and airtight 
conditions! 
4 weeks 
control sera / 
standard sera 
after opening at 2-8°C until expiry date; 
24 months from 
date of production 
conjugate ready-to-use solution, at 2-8°C 
 
Avoid contamination (sterile tips!) 
until expiry date 
28 months from 
date of production 
dilution buffer after opening at 2-8°C 
Discard cloudy solutions! 
 
unopened 
24 months 
 
until expiry date; 
36 months from 
date of production 
washing solution concentrate after opening at 2-8°C 
working dilution at 2-8°C 
working dilution at room temperature 
 
Bottles used for the working dilution should be cleaned 
regularly, discard cloudy solutions. 
until expiry date 
2 weeks 
1 week 
substrate ready-to-use solution at 2-8°C, protected from light! 
 
Avoid contamination (sterile tips!) Discard when solution 
turns yellow (extinction against distilled water > 0.25). 
until expiry date 
24 months from 
date of production 
stopping solution after opening at room temperature until expiry date 
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7. TEST PROCEDURE SERION ELISA classic 
 
7.1 Evidence of deterioration 
 
ONLY USE SERION ELISA CLASSIC REAGENTS FOR TEST PROCEDURE, SINCE 
ALL REAGENTS ARE MATCHED. IN PARTICULAR STANDARD AND CONTROL 
SERA ARE DEFINED EXCLUSIVELY FOR THE TEST KIT TO BE USED. DO NOT 
USE THEM IN OTHER LOTS. DILUTION BUFFER, WASHING SOLUTION AND 
SUBSTRATE SOLUTION CAN BE USED FOR ALL SERION ELISA CLASSIC KITS 
IRRESPECTIVE OF THE LOT AND THE TEST. 
 
THERE ARE THREE DIFFERENT CONJUGATE CONCENTRATIONS FOR EACH 
IMMUNOGLOBULIN CLASS: LOW, MEDIUM, HIGH 
 
THE CLASSIFICATION IS WRITTEN ON EACH LABEL AS FOLLOWS: 
 
E.G. IGG + LOWLY CONCENTRATED IGG 
CONJUGATE IGG ++ MEDIUM 
CONCENTRATED IGG CONJUGATE 
IGG +++ HIGHLY CONCENTRATED 
IGG CONJUGATE 
 
IN RARE CASES THE USE OF SPECIAL CONJUGATE IS NECESSARY TO 
GUARANTEE CONSISTENT QUALITY FOR OUR PRODUCTS. SPECIAL 
CONJUGATES ARE PRODUCED IN A SEPARATE LOT AND DO NOT WEAR THE 
“+” SIGN. THEREFORE, SPECIAL CONJUGATES ARE NOT EXCHANGEABLE 
WITH OTHER CONJUGATES. 
 
Please pay close attention to notifications on labels! 
 
UNOPENED, ALL COMPONENTS OF THE SERION ELISA CLASSIC KITS MAY BE 
USED UP TO THE DATES GIVEN ON THE LABELS, IF STORED AT +2°C TO +8°C. 
COMPLETE STABILITY AND STORAGE DATA ARE DESCRIBED UNDER “6. 
STORAGE AND STABILITY”. 
 
EACH REAGENT HAS BEEN CALIBRATED AND OPTIMIZED FOR THE TEST. 
DILUTION OR ALTERATION OF THESE REAGENTS MAY RESULT IN A LOSS OF 
SENSITIVITY. 
 
AVOID EXPOSURE OF REAGENTS TO STRONG LIGHT DURING STORAGE AND 
INCUBATION. REAGENTS MUST BE TIGHTLY CLOSED TO AVOID 
EVAPORATION AND CONTAMINATION WITH MICROORGANISMS SINCE 
INCORRECT TEST RESULTS COULD OCCUR DUE TO INTERFERENCE FROM 
PROTEOLYTIC ENZYMES. 
 
TO OPEN THE PRESS-SEAL BAG PLEASE CUT OFF THE TOP OF THE MARKED 
SIDE, ONLY. DO NOT USE THE STRIPS IF THE ALUMINUM BAG IS DAMAGED 
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OR IF THE PRESS-SEAL BAG WITH REMAINING STRIPS AND DESICCANT WAS 
NOT PROPERLY CLOSED. 
 
BRING ALL REAGENTS TO ROOM TEMPERATURE BEFORE TESTING. 
 
USE ASEPTIC TECHNIQUES FOR REMOVING ALIQUOTS FROM THE REAGENT 
TUBES TO AVOID CONTAMINATION. TO AVOID FALSE POSITIVE RESULTS 
ENSURE NOT TO CONTACT OR SPRINKLE THE TOP-WALLS OF WELLS WHILE 
PIPETTING CONJUGATE. BE CAREFUL NOT TO MIX THE CAPS OF THE BOTTLES 
AND/OR VIALS. REPRODUCIBILITY DEPENDS ON THOROUGH MIXING OF THE 
REAGENTS. SHAKE THE FLASKS CONTAINING CONTROL SERA BEFORE USE 
AND ALSO ALL SAMPLES AFTER DILUTION (E.G. BY USING A MONOMIXER). 
 
BE SURE TO PIPETTE CAREFULLY AND COMPLY WITH THE GIVEN 
INCUBATION TIMES AND TEMPERATURES. SIGNIFICANT TIME DIFFERENCES 
BETWEEN PIPETTING THE FIRST AND LAST WELL OF THE MICROTITER PLATE 
WHEN FILLING SAMPLES/CONTROL SERA, CONJUGATE OR SUBSTRATE MAY 
RESULT IN DIFFERENT 
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„PRE INCUBATION“ TIMES, WHICH MAY INFLUENCE THE PRECISION AND 
REPRODUCIBILITY OF THE RESULTS. 
 
OPTIMUM RESULTS CAN ONLY BE ACHIEVED IF SERION ELISA CLASSIC 
INSTRUCTIONS ARE FOLLOWED STRICTLY. 
 
THE TEST IS NOT VALID, IF THE LOT-SPECIFIC VALIDATION CRITERIA ON THE 
QUALITY CONTROL CERTIFICATE ARE NOT FULFILLED. 
 
INADEQUATE WASHING WILL AFFECT THE TEST RESULTS: 
THE WASHING PROCEDURE SHOULD BE CARRIED OUT CAREFULLY. IF THE 
WASHING PROCEDURE IS CARRIED OUT AUTOMATICALLY FOLLOW THE 
INSTRUCTION MANUAL OF THE RESPECTIVE WASHER. FLAT BOTTOM WELLS 
ARE USED FOR SERION ELISA CLASSIC. ALL WELLS SHOULD BE FILLED WITH 
EQUAL VOLUMES OF WASHING BUFFER. AT THE END OF THE PROCEDURE 
ENSURE THAT THE WELLS ARE FREE OF ALL WASHING BUFFER BY TAPPING 
THE INVERTED MICROTEST PLATE ON A PAPER TOWEL. AVOID FOAM! DO NOT 
SCRATCH COATED WELLS DURING WASHING AND ASPIRATION. IF USING AN 
AUTOMATED WASHER, ENSURE IT IS OPERATING CORRECTLY. 
 
 
7.2 Sample preparation and storage 
 
LIPAEMIC, HEMOLYTIC OR ICTERIC SAMPLES SHOULD ONLY BE TESTED 
WITH RESERVATIONS ALTHOUGH IN OUR TESTING NO NEGATIVE INFLUENCE 
HAS BEEN FOUND. OBVIOUSLY CONTAMINATED SAMPLES (SERUM OR 
PLASMA) SHOULD NOT BE TESTED DUE TO THE RISK OF WRONG RESULTS. 
 
SERUM OR PLASMA (EDTA, CITRATE, HEPARIN) COLLECTED ACCORDING TO 
STANDARD LABORATORY METHODS ARE SUITABLE SAMPLES. 
 
Samples must not be thermally inactivated. 
 
 
7.2.1 Sample preparation 
 
BEFORE RUNNING THE TEST, SAMPLES MUST BE DILUTED IN DILUTION BUFFER 
(V1 + V2) AS FOLLOWS: 
 
 
SERION ELISA classic Leptospira IgG 
 
 
  
sample   V1 + V2 = 1+100 
 44  
AFTER DILUTION AND BEFORE PIPETTING INTO THE MICROTITER PLATE THE 
SAMPLES MUST BE MIXED THOROUGHLY TO PREPARE A HOMOGENOUS 
SOLUTION. 
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SERION ELISA classic Leptospira IgM 
 
RHEUMATOID FACTOR-INTERFERENCE: 
RHEUMATOID FACTORS ARE AUTOANTIBODIES MAINLY OF THE IGM-
CLASS, WHICH PREFERABLY BIND TO IGG-IMMUNE-COMPLEXES. THE 
PRESENCE OF NON-SPECIFIC IGM-ANTIBODIES (RHEUMATOID FACTORS) CAN 
LEAD TO FALSE-POSITIVE RESULTS IN THE IGM-ASSAY. FURTHERMORE, 
THE POSSIBILITY EXISTS, THAT WEAK-BINDING PATHOGEN-SPECIFIC IGM-
ANTIBODIES ARE DISPLACED BY STRONGER-BINDING IGG-ANTIBODIES. IN 
THIS CASE, IGM-DETECTION CAN LEAD TO FALSE-NEGATIVE RESULTS. 
THEREFORE IT IS NECESSARY TO PRETREAT SAMPLES WITH RHEUMATOID 
FACTOR-ABSORBENS PRIOR TO IGM DETECTION (SERION RHEUMATOID 
FACTOR-ABSORBENT Z200 (20 ML/100 TESTS)). 
 
BEFORE RUNNING THE TEST, RHEUMATOID FACTOR-ABSORBENT (V1) MUST BE 
DILUTED 1+4 IN DILUTION BUFFER (V2). 
 
 
SAMPLES (V4) MUST BE DILUTED IN THIS RF-DILUTION BUFFER (V3) 
 
 
 
 
7.2.2 Sample storage 
 
THE STOPPERED SAMPLES CAN BE STORED IN A REFRIGERATOR UP TO 7 DAYS  
AT  2-8°C.  EXTENDED STORAGE IS POSSIBLE AT  -20°C. 
 
AVOID REPEATED FREEZING AND THAWING OF SAMPLES. 
 
Diluted samples can be stored at 2-8°C for one week. 
  
Rf-absorbent  V1 + V2 = 1 + 4 
  
sample   V4 + V3 = 1+100 
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7.3. Preparation of kit reagents 
 
7.3.1 Microtest strips 
MICROTEST STRIPS IN FRAME ARE PACKED WITH DESICCANT IN AN 
ALUMINUM BAG. TAKE UNREQUIRED CAVITIES OUT OF THE FRAME AND 
PUT THEM BACK INTO THE PRESS-SEAL BAG. CLOSE PRESS-SEAL BAG 
CAREFULLY TO ENSURE AIRTIGHT CONDITIONS. 
 
7.3.2 Control sera / standard sera 
CONTROL AND STANDARD SERA ARE READY-TO-USE AND MUST NOT BE 
DILUTED ANY FURTHER. THEY CAN BE USED DIRECTLY FOR THE TEST 
RUN. 
 
FOR EACH TEST RUN AND FOR EACH TEST SYSTEM - INDEPENDENT OF 
THE NUMBER OF MICROTEST STRIPS TO BE USED - CONTROL AND 
STANDARD SERA MUST BE INCLUDED. THE CUT-OFF-CONTROL SHOULD 
BE SET UP IN DUPLICATE. WITH THE QUANTITATIVE TESTS THE 
STANDARD SERUM SHOULD ALSO BE SET UP IN DUPLICATE. 
 
DO NOT TREAT CONTROL SERA WITH RF-ABSORBENT. 
 
7.3.3 Anti-human-IgG-, IgM- or IgA-AP-conjugate (ready-to-use) 
PLEASE DO NOT MIX UP CONJUGATES FROM DIFFERENT KITS. THEY ARE 
OPTIMIZED FOR EACH LOT. CONJUGATES ARE EXCHANGEABLE AS 
DESCRIBED IN 7.1. 
AVOID CONTAMINATION OF READY-TO-USE CONJUGATES (PLEASE POUR 
SUFFICIENT FOR TEST INTO A SECONDARY CONTAINER TO AVOID 
REPEATEDLY PIPETTING FROM THE ORIGINAL BOTTLE). 
 
 
7.3.4 Washing solution 
DILUTE WASHING BUFFER CONCENTRATE (V1) 1:30 WITH DISTILLED 
WATER TO A FINAL VOLUME OF V2. 
 
EXAMPLE: 
buffer concentrate (V1) final volume (V2) 
33.3 ml 1000 ml 
1 ml 30 ml 
 
 
7.3.5 Dilution buffer for samples (ready-to-use) 
 
7.3.6 Substrate (ready-to-use) 
TO AVOID CONTAMINATION USE GLOVES. FOR PIPETTING SUBSTRATE 
SOLUTION USE STERILE TIPS ONLY! 
 
 
7.3.7 Stopping solution (ready-to-use) 
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7.4. Overview - test procedure 
 
Leptospira IgG/IgM 
quantitative 
 
IN CASE OF IGM-DETECTION ABSORPTION OF 
RHEUMATOID FACTOR! SAMPLE DILUTION 
1 + 100 
  
 
PIPETTE DILUTED SAMPLES AND READY-TO-
USE CONTROL SERA / STANDARD SERA INTO 
THE MICROTEST WELLS (100 µL) 
  
 
 
 
WASH 
  
 
PIPETTE CONJUGATE SOLUTION (100 µL) 
  
 
 
 
WASH 
  
 
PIPETTE SUBSTRATE SOLUTION (100 µL) 
  
 
 
 
PIPETTE STOPPING SOLUTION (100 µL) 
  
 
INCUBATION 60 
MIN./37°C 
MOIST CHAMBER 
INCUBATION 30 
MIN./37°C 
MOIST CHAMBER 
INCUBATION 30 
MIN./37°C 
MOIST CHAMBER 
READ EXTINCTION AT 405 NM 
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7.5 Test procedure 
 
1. Place the required number of cavities in the frame and prepare a protocol sheet. 
 
2. Add each 100 µl of diluted sample or ready-to-use controls into the appropriate wells of 
microtest strips. Spare one well for substrate blank, e.g.: 
 
IgG/IgM quantitative 
well A1 substrate blank 
well B1 negative control 
well C1 standard serum 
well D1 standard serum 
well E1 sample 1.... 
 
3. Sample incubation for 60 minutes (+/- 5 min) at 37°C (+/- 1°C) in moist chamber 
 
4. After incubation wash all wells with washing solution (by automated washer or manually): 
- aspirate or shake out the incubation solution 
- fill each well with 300 µl washing solution 
- aspirate or shake out the washing buffer 
- repeat the washing procedure 3 times (altogether 4 times!) 
- dry by tapping the microtest plate on a paper towel 
 
5. Addition of conjugate 
ADD 100 µL OF IGG-/IGM-/IGA-CONJUGATE (READY-TO-USE) TO THE 
APPROPRIATE WELL (EXCEPT SUBSTRATE BLANK) 
 
6. Conjugate incubation for 30 minutes (+/- 1 min) * at 37°C (+/- 1°C) in moist chamber. 
 
7. After incubation wash all wells with washing solution (see above) 
 
8. Addition of substrate 
ADD 100 µL SUBSTRATE SOLUTION (READY-TO-USE) TO EACH WELL 
(INCLUDING WELL FOR SUBSTRATE BLANK!) 
 
9. Substrate incubation for 30 minutes (+/- 1 min) * at 37°C (+/- 1°C) in moist chamber. 
 
10. Stopping of the reaction 
ADD 100 µL STOPPING SOLUTION TO EACH WELL, SHAKE MICROTEST PLATE 
GENTLY TO MIX. 
 
11. Read optical density 
READ OD WITHIN 60 MINUTES AT 405 NM AGAINST SUBSTRATE BLANK, 
REFERENCE WAVE LENGTH BETWEEN 620 NM AND 690 NM (E.G. 650 NM). 
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* 
Please note, that under special working-conditions internal laboratory adaptations of the incubation times 
could be necessary. 
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8. TEST EVALUATION 
SERION ELISA classic Leptospira IgG/IgM (quantitative) 
 
8.1 Single-point quantification with the 4PL method 
 
OPTIMIZED ASSIGNMENT OF EXTINCTION SIGNALS TO QUANTITATIVE 
VALUES IS GUARANTEED BY USING NON-LINEAR FUNCTIONS, WHICH 
ADJUST A SIGMOIDE CURVE WITHOUT ANY FURTHER TRANSFORMATION TO 
OD-VALUES. 
 
Determination of antibody concentrations with the SERION ELISA classic is carried out by the 
logistic-log-model (4 PL; 4 parameter) which is ideal for exact curve-fitting. It is based on the 
formula: 
 
THE PARAMETERS A, B, C, AND D ARE REPRESENTATIVE FOR THE EXACT SHAPE 
OF THE CURVE: 
 
1. lower asymptote ¢ parameter A 
2. slope of the curve ¢ parameter B 
3. turning point ¢ parameter C 
4. upper asymptote ¢ parameter D 
FOR EACH LOT THE STANDARD CURVE IS EVALUATED BY INSTITUT 
VIRION\SERION GMBH (WÜRZBURG, GERMANY) IN SEVERAL REPEATED TEST 
RUNS UNDER OPTIMAL CONDITIONS. TIME CONSUMING AND COST 
INTENSIVE CONSTRUCTION OF THE STANDARD CURVE BY THE USER IS NOT 
NECESSARY. 
 
FOR EVALUATION OF ANTIBODY CONCENTRATIONS A LOT SPECIFIC 
STANDARD CURVE AS WELL AS A LOT SPECIFIC EVALUATION TABLE IS 
INCLUDED WITH EACH TEST KIT. APPROPRIATE EVALUATION SOFTWARE IS 
AVAILABLE ON REQUEST. 
 
TO COMPENSATE FOR NORMAL TEST VARIATIONS AND ALSO FOR TEST RUN 
CONTROL A STANDARD SERUM IS USED IN EACH INDIVIDUAL TEST RUN. FOR 
THIS CONTROL SERUM A ‘’REFERENCE VALUE’’ WITH A VALIDITY RANGE IS 
DETERMINED BY THE QUALITY CONTROL OF THE PRODUCER. WITHIN THIS 
RANGE A CORRECT QUANTIFICATION OF ANTIBODY CONCENTRATION IS 
ENSURED. SINCE THE STANDARD SERUM IS NOT NECESSARILY A POSITIVE 
CONTROL, THE VALUE OF THE STANDARD SERUM MAY BE BORDERLINE OR 
NEGATIVE IN SOME ELISA TESTS. 
 
 
1 + e B(C - In conc.) 
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8.2 Criteria of validity 
 
- the substrate blank must be OD < 0.25 
- the negative control must be negative 
- quantitative ELISA: the mean OD-value of the standard serum must be within the validity range, 
which is given on the lot specific quality control certificate of the kit (after subtraction of the 
substrate blank!) 
- qualitative ELISA: the mean OD-value of the positive control must be within the validity range, 
which is given on the lot specific quality control certificate of the kit (after subtraction of the 
substrate blank!) 
- the variation of OD-values may not be higher than 20%. 
IF THESE CRITERIA ARE NOT MET, THE TEST IS NOT VALID AND MUST BE 
REPEATED. 
 
 
8.3 Calculation 
SERION ELISA classic Leptospira IgG/IgM (quantitative) 
 
8.3.1 Non-automated evaluation 
 
FOR THE TEST EVALUATION A STANDARD CURVE AND AN EVALUATION 
TABLE ARE INCLUDED IN THE TEST KIT SO THAT THE OBTAINED OD-VALUES 
MAY BE ASSIGNED TO THE CORRESPONDING ANTIBODY ACTIVITY. THE 
REFERENCE VALUE AND THE VALIDITY RANGE OF THE STANDARD SERUM IS 
GIVEN ON THE EVALUATION TABLE (QUALITY CONTROL CERTIFICATE). 
 
The blank (A1) must be subtracted from all OD-values prior to the evaluation. 
 
 
Method 1: Qualitative Evaluation 
 
TO FIX THE CUT-OFF RANGES PLEASE MULTIPLY THE MEAN VALUE OF THE 
MEASURED STANDARD-OD WITH THE NUMERICAL DATA OF THE 
CERTIFICATE OF QUALITY CONTROL (SEE SPECIAL CASE FORMULAS), E.G.: 
OD = 0.502 X MW (STD) WITH UPPER 
CUT-OFF OD = 0.352 X MW (STD) 
WITH LOWER CUT-OFF 
IF THE MEASURED MEAN ABSORBANCE VALUE OF THE STANDARD SERUM 
IS 0.64, THE RANGE OF THE CUT- OFF IS IN BETWEEN 0.225-0.321. 
 
 
METHOD 2: CONTINUOUS DETERMINATION OF ANTIBODY ACTIVITIES USING 
THE STANDARD CURVE. 
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SO CALLED INTERASSAY VARIATIONS (DAY TO DAY DEVIATIONS AND 
LABORATORY TO LABORATORY DEVIATIONS) ARE COMPENSATED BY 
MULTIPLICATION OF THE CURRENT MEASURED VALUE OBTAINED WITH A 
SAMPLE WITH THE CORRECTION FACTOR F. THIS FACTOR IS CALCULATED 
AS FOLLOWS: 
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THE PROCEDURE IS NECESSARY TO ADJUST THE CURRENT LEVEL OF THE TEST 
OF THE USER WITH THE LOT- SPECIFIC STANDARD CURVE. 
 
FIRST, DAILY DEVIATIONS HAVE TO BE CORRECTED BY CALCULATING A 
FACTOR (CORRECTION FACTOR F): 
 
1. The mean of the two OD-values of the standard serum has to be calculated and checked that it is 
within the given validity range. 
2. Calculation of the factor “F”: the given reference value is divided by the mean of the 
extinction of the standard serum: 
F = REFERENCE VALUE EXTINCTION STANDARD SERUM / MEAN VALUE 
EXTINCTION STANDARD SERUM. 
3. All measured values of samples are multiplied by “F”. 
4. Antibody activities in IU/ml or U/ml can be determined from the standard curve with the 
corrected values. 
 
 
8.3.2 Automatic test evaluation with 
SERION easy base 4PL-Software/SERION evaluate-Software 
 
AFTER INPUT OF THE 4 PARAMETERS AND THE REFERENCE VALUE OF THE 
STANDARD SERUM, ANTIBODY ACTIVITIES ARE CALCULATED ONLINE. IF 
THE OPTICAL DENSITY OF THE STANDARD IS OUT OF THE VALID RANGE, THE 
FOLLOWING MESSAGE WILL APPEAR: 
 
SERION easy base 4PL-Software: 
 
”Standards are not in tolerance range” and/or “Distance between standards is greater 
than 20 %.” 
 
SERION evaluate-Software: 
 
“Standard values out of ranges in following groups: Group 1-24. Standard value 
differ more than 20% in following groups: Group 1-24.” 
 
IN THESE CASES THE TEST RUN IS INVALID AND SHOULD BE REPEATED. 
 
PARAMETERS AND REFERENCE VALUE NEED TO BE CHANGED ONLY IF 
THERE IS A CHANGE OF LOT (EVALUATION TABLE SHOWS PARAMETERS 
AND REFERENCE VALUES). CORRECT INPUT OF THE LOT SPECIFIC DATA CAN 
BE CHECKED ON THE BASIS OF THE IU/ML OR U/ML ASSIGNED TO THE 
STANDARD SERUM. THE CALCULATED MEAN VALUE OF THE UNITS HAS TO 
CORRESPOND TO THE UNIT VALUE INDICATED ON THE LOT SPECIFIC 
CERTIFICATE. THERE IS AN AUTOMATIC CORRECTION OF THE MEASURED 
VALUES. IN THE STANDARD VERSION THE PRINTOUT DISPLAYS THE 
FOLLOWING: 
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SAMPLE 
CODE OD-
VALUE 
IU/ML OR 
U/ML 
EVALUATIO
N 
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9. STATEMENTS OF WARNING 
 
9.1 Statements of warning 
 
THE SERION ELISA CLASSIC IS ONLY DESIGNED FOR QUALIFIED PERSONNEL 
WHO ARE FAMILIAR WITH GOOD LABORATORY PRACTICE. 
ALL KIT REAGENTS AND HUMAN SPECIMEN SHOULD BE HANDLED 
CAREFULLY, USING ESTABLISHED GOOD LABORATORY PRACTICE. 
 
- This kit contains human blood components. Although all control- and cut-off-sera have been 
tested and found negative for HBs-Ag-, HCV- and HIV-antibodies, they should be considered 
potentially infectious. 
- Do not pipette by mouth. 
- Do not smoke, eat or drink in areas in which specimen or kit reagents are handled. 
- Wear disposable gloves, laboratory coat and safety glasses while handling kit reagents or 
specimen. Wash hands thoroughly afterwards. 
- Samples and other potentially infectious material should be decontaminated after the test run. 
- Reagents should be stored safely and be unaccessible to unauthorized access e.g. children. 
- Stopping solution: corrosive (C); cause acid burn (R34) 
USE SAFETY GLASSES, GLOVES AND LABORATORY COAT WHILE 
HANDLING! 
 
9.2 Disposal 
 
PLEASE OBSERVE THE RELEVANT STATUTORY REQUIREMENTS! 
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27 August 2018 
 
 
 
RE: Nicole Delgado 
MPH Student Thesis Project: HSC-SPH-18-0688   
“INVESTIGATION OF HANTAVIRUS AND LEPTOSPIROSIS AS POSSIBLE CONTRIBUTING 
CAUSES OF UNEXPLAINED KIDNEY DISEASE EPIDEMIC IN NICARAGUA” 
Reference number:  176220 
 
Dear Committee for the Protection of Human Subjects, 
 
Please accept this letter of support for the thesis work proposed at Baylor College of Medicine by Nicole 
Delgado. I am the Principal Investigator and Dr. Rebecca Fischer is the thesis Advisor here in our 
department. Ms. Delgado’s work will be of great public health importance and contribute to our 
overarching investigation into the cause of a mysterious disease causing a major public health crisis in 
Latin America. Please do not hesitate to contact Dr. Fischer directly at rebecca.fischer@bcm.edu if 
anything further is needed on our end. 
 
Sincerely, 
 
 
 
Kristy O. Murray, DVM, PhD 
 
 
 
Rebecca S.B. Fischer, MPH, PhD  
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Appendix VI: Variable Description Table 
 
Variable Name Variable Label 
sex Participant Sex 
agecat1 Age is 30+ (years) 
agecat2 Participant Age 
agecat3 Age is 25+ (years) 
agecat4 Age is 35+ (years) 
city City of Residence 
resid_chichi Lived in Chichigalpa 
drug Drug Use 
drugs Drugs 
drug_ever Drug Use (Current/Former) 
wk_isa_yrs Total years worked at ISA 
wk_isa_cat0 Total years worked at ISA (categorical) 
wk_isa_cat1 Total years worked at ISA (<5) 
wk_isa_cat3 Total years worked at ISA 
wk_isa_cat4 Total years worked at ISA >2 yrs 
wk_isa_cat5 Total years worked at ISA >10 yrs 
wk_Campo_cat1 Total years in Cane Fields (>5) 
wk_Campo_cat0 Total years in Cane Fields (categorical) 
wk_Campo_cat4 Total years worked at Field > 2 yrs 
wk_Campo_cat5 Total years worked at Field >10yrs 
occup_acarreo Works  in Paqueta/Carry 
occup_cosecha Works in Harvest (operario general) 
occup_camaron Works in Camaronera 
occup_plagas Works in Control de Pest 
occup_horno Works in Oven 
occup_maleza Works in Control de Weeds 
occup_quema Works in Burn (Field/Oven) 
occup_corte_m Works in Cut Sugar Cain - Mechanized 
occup_siembra Works in occup_Planting/Reseeding 
occup_riego Works in Irrigation/Drainage 
occup_rymma Automechanic 
occup_fabrica Works in Factory 
worksoil works with soil 
Campoworker Works in field (either soil and/or water) 
worksoil_road Type of Working Soil - Road  
worksoil_ditch Type of Working Soil - Ditch  
worksoil_aero Type of Working Soil - Aerosolizado 
worksoil_dry Type of Working Soil - Dry  
worksoil_wet Type of Working Soil - Wet 
worksoil_Campo Type of Working Soil - Field 
worksoil_other Type of Working Soil or Other_Spec 
 
Variable Name 
Variable Label 
rats_Casa Ever sees Rodents in Home 
rats_Casa_feces Ever sees Rodent Feces in Home 
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  rats_Casa_daily Sees Rodents in Home Daily 
rats_Casa_freq Sees Rodents in Home, Frequency 
rats_Casa_freq2 Sees Rodents in Home, Frequency 
handwash_Casa Handwash agudo Water from My House 
handwash_foun Handwash agudo Fountain 
handwash_ditch Handwash agudo Drain  
handwash_drain Handwash agudo Drainage Tube  
handwash_well Handwash Well 
handwash_truck Handwash Truck 
handwash_other Handwash Other 
handwash_always Handwash Always 
handwash_usualy Handwash Usually 
handwash_rarely Handwash Rarely 
handwash_never Handwash Never 
handwash_cat Handwash Catagorical 
drink_etoh_freq Drink etoh Frequently 
drink_etoh_otro drink_etoh_Other  
drink_etoh_ot   drink_etoh_Other1 
drink_etoh_ce drink_etoh_ 
drink_bottle  Drink from Bottle 
drink_fountain  in the field drinks water from fountain 
drink_truck 
  in the field drinks water from ISA 
drink_truck 
drink_well  in the field drinks water from a drink_well 
drink_ditch    
 in the field drinks water from the irrigation 
ditch 
drink_drain  
in the field drinks water from 
drink_drainage pipe 
drink_drain ditch 
 drinks water from the ditch or drainage 
tube 
wellwater_drink  Drinks Well Water at Home or Work 
ppe_gloves Used Gloves - Always/Occasionally/Never 
ppe_gloves_yn  Used Gloves - Yes/No 
ppe_glasses Used Protective Glasses 
ppe_glasses_yn  Used Protective Glasses - Yes/No 
ppe_mask Used Mask 
ppe_mask_yn  Used Mask - Yes/No 
ppe_nose Used Protective Nose Covering 
ppe_nose_yn  Used Protective Nose Covering - Yes/No 
ppe_pants  Used Long Pants 
ppe_pants_yn Used Long Pants - Yes/No 
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Appendix VII: Previous Study Acute Case Interview Form 
SECTION 1: Acute Case 
I'm going to ask you about what happened when you were sick on:   
How long were you sick before going to the hospital? 
 □ the same day      □____ days      □____weeks    □I Don’t Know  
What time did your symptoms start?  _____:______  □Morning □Afternoon  □Night  □I Don’t 
Know 
Were you working at the time you got sick? □Yes       □ No □I Don’t Know 
 If you answer is Yes 
  What job were you currently working when you got sick? ____________________________ 
  How many hours of the day had you been working when your symptoms began? ______ 
  Did you feel very hot immediately when your symptoms began?  □Yes       □ No □I Don’t Know 
 
Please tell me if you had any of these symptoms during your illness (this episode, including the week before): 
Symptoms during the acute disease  Description or notes 
Fever □Yes       □No        □I Don’t Know Temp: ____. __ °C, duration: ___days  
Headache □Yes       □No        □I Don’t Know  
Abdominal pain □Yes       □No        □I Don’t Know  
Low back pain/Back pain □Yes       □No        □I Don’t Know  
Cervicalgia/Neck pain □Yes       □No        □I Don’t Know  
Arthralgia □Yes       □No        □I Don’t Know Which joint:  
Myalgia □Yes       □No        □I Don’t Know  
Chest pain □Yes       □No        □I Don’t Know  
Nausea □Yes       □No        □I Don’t Know  
Vomiting □Yes       □No        □I Don’t Know  
Diarrhea □Yes       □No        □I Don’t Know  
Muscle weakness □Yes       □No        □I Don’t Know  
Cold/Chills □Yes       □No        □I Don’t Know  
Cough □Yes       □No        □I Don’t Know  
Dyspnea/Difficulty breathing □Yes       □No        □I Don’t Know  
Fatigue/Discomfort □Yes       □No        □I Don’t Know  
Jaundice □Yes       □No        □I Don’t Know  
Tremors □Yes       □No        □I Don’t Know  
Rash □Yes       □No        □I Don’t Know Where: 
Difficulty or Pain with Urination □Yes       □No        □I Don’t Know  
Blurry vision □Yes       □No        □I Don’t Know  
Edema/Swelling □Yes       □No        □I Don’t Know Where: 
Cramps □Yes       □No        □I Don’t Know  
Paresthesia (ex. Burning/Prickling) □Yes       □No        □I Don’t Know  
Dizziness □Yes       □No        □I Don’t Know  
Confusion □Yes       □No        □I Don’t Know  
Red eyes □Yes       □No        □I Don’t Know  
Other symptoms: 
 
How many nights did you spend in the hospital? □______ night(s)  □I Don’t Know 
How long did the symptoms last (in total)?  □____ days □____ weeks □ I Don’t Know  
 Occupation 
I want to know about the job you were working on: 
What was your job/occupation?  
□ Hauler/loader 
□ Shrimp farm worker 
□ Pest control 
□ Weed control 
□ Sugarcane cutting, mechanical 
□ Sugarcane cutting, manual 
□ Seed cutting 
□ Factory 
□ General Crop Operator 
□ Fertilizer Operator 
□ Oven Operator 
□ Sugarcane burning 
□ Sowing/Reseeding 
□ Irrigation/Drainage 
□ Auto mechanic 
□ Other: ____________________________ 
 
Acute Case Date  
(from Case Report, Form A): 
_____/_____/________ 
 
Acute Case Date (from Form A):  
 
_____/_____/________ 
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What is the schedule that you normally worked?  
□ 6am     □ 7am       □ 8am       □ 9am       □ 10am       □ 11am       □ 12md    □ 1pm     □ 2pm    □ 3pm   □ 4pm    □ 5pm     
□ 6pm     □ 7pm       □ 8pm       □ 9pm       □ 10pm       □ 11pm       □ 12mn    □ 1am     □ 2am    □ 3am   □ 4am    □ 5am  
If you work shift, the second shift:  
□ 6am     □ 7am       □ 8am       □ 9am       □ 10am       □ 11am       □ 12md    □ 1pm     □ 2pm    □ 3pm   □ 4pm    □ 5pm     
□ 6pm     □ 7pm       □ 8pm       □ 9pm       □ 10pm       □ 11pm       □ 12mn    □ 1am     □ 2am    □ 3am   □ 4am    □ 5am  
How many days a week?     □ ≤3 days     □ 4 days       □ 5 days       □ 6 days       □ 7 days  □ other ____________ 
Which months did you work during this season?  
 □ Jan       □ Feb       □ Mar       □ April        □ May       □ Jun       □ Jul         □ Aug       □ Sep       □ Oct     □ Nov       □ Dec        
When did you start working this season? _____/_____/________ 
What other work were you doing during the 3 weeks before you got sick? 
 □ Only the same as above 
 □ Other: _________________________________________________________________________ 
Did your work imply that you are working on water contact (standing or digging in water)?  □Yes    □No     □I Don’t Know 
 If your answer is Yes: What type of water? (Check all that apply)  
   □Irrigation      □Drainage      □Water source        □Rain          □Wet floor     
   □Standing water        □Shrimp water   □Other: ____________________ 
Did your work imply that you are working in contact with soil? (ex. contact with skin or respiration) □Yes    □No     □I Don’t Know 
 If your answer is Yes: What type of soil? (Check all that apply)  
   □Dry soil      □Wet soil      □Field soil       □Drainage soil      □Aerosolized soil 
   □Ground on the Road           □Other: ____________________ 
Did your work imply that you are working in contact with the burned cane?    □Yes    □No     □I Don’t Know 
 If your answer is Yes: What type of contact? (Check all that apply)  
   □Burning the sugar cane      □ Pick up the burnt cane      □Oven work         
   □Loading the burned sugar cane               □Other: ____________________ 
 
 
 
Does your work imply that you are working in contact with chemicals?   □Yes    □No     □I Don’t Know 
 If your answer is Yes: What type of chemicals? (Check all that apply)  
   □pesticide      □herbicide      □fertilizer        □factory chemical(s)    □Other:__________________ 
  Do you know specifically which chemical(s)? __________________________________________________ 
  What type of contact? (Check all that apply)  
   □Application      □Fabric      □Skin contact     □Ingestion     □Dust/Inhalation 
   □Contact with eyes    □Other: ____________________ 
Where did you get drinking water in the field? (Check all that apply) 
  □Water from home       □Fountain          □Irrigation      □Drainage tube        □Water well         □Water truck 
  □Bottled water □Other: ______________________________________ 
 If you answer is Water from home:  What water do you drink if you have finished the water you brought?  
                         _____________________________________________________ 
Do you wash your hands before you eat in the field? 
 □Yes, Always         □Usually        □Rarely    □Other ________    □ No, Never □I Don’t Know 
 If your answer is Yes: Where do you wash your hands? (Check all that apply) 
   □Water from home       □Fountain          □Irrigation      □Drainage tube        □Water well        
   □Water truck      □Bottled water □Other: ______________________________________  
Which of the following do you use when you are working? 
Gloves □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Glasses or sunglasses □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Mouth cover (mask) □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Nose cap □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Long pants □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Long sleeved shirt □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Boots □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Waterproof boots □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Hat or cap □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
 
Did you work any other job(s) at the time? (ex. mani, plantains, extraction or others jobs) □Yes    □No     □I Don’t Know 
 If your answer is Yes:  Describe the other job(s) _______________________ 
 65 
 
Have you ever seen rats while working? □Yes       □No        □I Don’t Know 
Have you ever had the heat stress while working?  □Yes       □No        □I Don’t Know  
If your answer is Yes:   
Have you ever had to stop working because you had the heat stress? □Yes       □No        □I Don’t Know 
Have you ever had dehydration while working?  □Yes       □No        □I Don’t Know 
 If your answer is Yes: 
 Have you ever had to stop working because of dehydration?       □Yes       □No        □I Don’t Know 
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SECTION 2: 
Are you accustomed to taking pills or medications, for example, when you have a pain or a fever? Please think about all the 
prescriptions, self-treatment, natural treatments that you normally use. □Yes    □No     □I Don’t Know 
 
Please tell me if you have ever taken any of the following medications.       (Ask about all) 
 How often do you have an episode while taking these 
pain pills? 
How many days do 
you take during 
each occurrence? 
How much time has 
passed since the last 
time you took pills? 
□antibiotic 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□amoxicillin 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□ciprofloxacin 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□gentamicin 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□penicillin 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□trimethoprim 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□acetaminophen/ 
paracetamol 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□ibuprofen 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□naproxen 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□metamizole 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□diclofenac 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□diclofenac gel 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□ranitidine 
(zantac) 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□omeprazole 
(Prilosec) 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□ 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
  
□ 
□every:  ____days      ____weeks    ____months            
□less than 1/year                                       □never 
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Which one did you use in the week before you became sick (the acute case date)? (Check all that apply)  
□None         □antibiotic □acetaminophen/paracetamol □ibuprofen □omeprazole (Prilosec)  
□ranitidine (zantac) □ Other_____________________  □I Don’t Know 
Which type do you use to treat your symptoms/disease during the occurrence? (Check all that apply)  
□None         □antibiotic □acetaminophen/paracetamol □ibuprofen □omeprazole (Prilosec)  
□ranitidine (zantac) □ Other_____________________  □I Don’t Know 
 
Has there been a time a doctor told you that you have elevated creatine or any kidney problem?  □Yes    □No     □I Don’t Know 
If the answer is Yes:  When? _____________________________  (Age, Date, or Time since then)   
 
Has a doctor ever told you that you have… (Please ask about all) 
Health condition  
When? 
(Date or age) 
Description and notes 
Asthma □Yes       □No        □I Don’t 
Know 
  
Anemia □Yes       □No        □I Don’t 
Know 
  
Diabetes □Yes       □No        □I Don’t 
Know 
  
Gout □Yes       □No        □I Don’t 
Know 
  
Heart disease □Yes       □No        □I Don’t 
Know 
  
Hepatitis □Yes       □No        □I Don’t 
Know 
  
Hepatic disease □Yes       □No        □I Don’t 
Know 
  
Hypertension □Yes       □No        □I Don’t 
Know 
  
Kidney stones □Yes       □No        □I Don’t 
Know 
  
Cystitis □Yes       □No        □I Don’t 
Know 
  
Other problem/renal disease □Yes       □No        □I Don’t 
Know 
  
Sexually transmitted disease □Yes       □No        □I Don’t 
Know 
  
Frequent urinary tract infections (UTIs) □Yes       □No        □I Don’t 
Know 
  
Pancreatitis □Yes       □No        □I Don’t 
Know 
  
Azotemia □Yes       □No        □I Don’t 
Know 
  
Leptospirosis □Yes       □No        □I Don’t 
Know 
  
Malaria □Yes       □No        □I Don’t 
Know 
  
Chagas □Yes       □No        □I Don’t 
Know 
  
Dengue □Yes       □No        □I Don’t 
Know 
  
Chikungunya □Yes       □No        □I Don’t 
Know 
  
Zika □Yes       □No        □I Don’t 
Know 
  
□ Other health condition    
□ Other health condition    
 
Have any of your parents or grandparents have… 
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Health condition  Who? 
Diabetes □Yes       □No        □I Don’t Know  
Gout □Yes       □No        □I Don’t Know  
Heart disease □Yes       □No        □I Don’t Know  
Hepatic disease □Yes       □No        □I Don’t Know  
Hypertension/High blood pressure □Yes       □No        □I Don’t Know  
Kidney stones □Yes       □No        □I Don’t Know  
Cystitis □Yes       □No        □I Don’t Know  
Other problem/kidney disease □Yes       □No        □I Don’t Know  
Frequent urinary tract infections (UTIs) □Yes       □No        □I Don’t Know  
Pancreatitis □Yes       □No        □I Don’t Know  
Azotemia □Yes       □No        □I Don’t Know  
Do you smoke or have smoked at any time in your life?   
□ Yes 
□ Yes, but only in the past 
   □ No, never   
   □ I don’t know       
Did you drink or have you drank alcohol? 
     □ Yes 
□ Yes, but only in the past 
   □ No, never   
    □ I don’t know       
Did you take or have you taken Lija?   
□ Yes 
□ Yes, but only in the past 
   □ No, never   
    □ I don’t know   
Did you take or have you taken drugs?   
□ Yes → What class?_____________________________________________________ 
    How often? 
     □ Daily   □ 3-4/week      □ 1-2/week      □ 1-2/month     □ Rarely     
    □Other:____________ 
□ Yes, but only in the past → What class?________________________________________ 
    □ No, never  
    □ I don’t know 
Do you use or have you used traditional medicine?  
   □ Yes → Which?  □ Red radish      □ Green radish       □ Basil         □ Noni  
    □ Horse tail     □ Malago     □Chamomile □ Other(s): _____________________ 
    How often? 
     □ Daily   □ 3-4/week      □ 1-2/week      □ 1-2/moth     □ Rarely   
□Other: ____________    
   □ Yes, but only in the past → Which?  □Red radish      □ Green radish       □ Basil      □ Noni  
    □ Horse tail     □ Malago     □ Chamomile     □ Other: _____________________ 
   □ No, never  
   □ I don’t know 
 
Have you ever been bitten by any insects, rats, or other animal?   □Yes    □No     □I Don’t Know 
If the answer is Yes: Which ones? (Check all that apply)    
□ Mosquitoes       □ Scorpion       □ Spider       □Snake    
□ Rat       □ Dog     □ Cat       □ Other_______________________________ 
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SECTION 3:  Subjective Case 
In the past, have you ever thought the it is the same type of disease before the episode of           ?    
□Yes    □No     □I Don’t Know 
*If the answer = “No” or if the date is within two weeks of the Acute Case Date→ MOVE on to SECTION 4* 
When was the first time it started? What day?      or ¿How long ago did it start? 
                     ________________ 
If the Date is less than a week before the Acute Case Date → MOVE on to SECTION 4* 
Please tell me if you had any of the following symptoms during your disease in that moment:  
Symptoms during the acute disease  Description or notes 
Fever □Yes       □No        □I Don’t Know Temp: ____. __ °C, duration: ___days  
Headache □Yes       □No        □I Don’t Know  
Abdominal pain □Yes       □No        □I Don’t Know  
Low back pain/Back pain □Yes       □No        □I Don’t Know  
Cervicalgia/Neck pain □Yes       □No        □I Don’t Know  
Arthralgia □Yes       □No        □I Don’t Know Which joint:  
Myalgia □Yes       □No        □I Don’t Know  
Chest pain □Yes       □No        □I Don’t Know  
Nausea □Yes       □No        □I Don’t Know  
Vomiting □Yes       □No        □I Don’t Know  
Diarrhea □Yes       □No        □I Don’t Know  
Muscle weakness □Yes       □No        □I Don’t Know  
Cold/Chills □Yes       □No        □I Don’t Know  
Cough □Yes       □No        □I Don’t Know  
Dyspnea/Difficulty breathing □Yes       □No        □I Don’t Know  
Fatigue/Discomfort □Yes       □No        □I Don’t Know  
Jaundice □Yes       □No        □I Don’t Know  
Tremors □Yes       □No        □I Don’t Know  
Rash □Yes       □No        □I Don’t Know Where: 
Difficulty or Pain with Urination □Yes       □No        □I Don’t Know  
Blurry vision □Yes       □No        □I Don’t Know  
Edema/Swelling □Yes       □No        □I Don’t Know Where: 
Cramps □Yes       □No        □I Don’t Know  
Paresthesia (ex. Burning/Prickling) □Yes       □No        □I Don’t Know  
Dizziness □Yes       □No        □I Don’t Know  
Confusion □Yes       □No        □I Don’t Know  
Red eyes □Yes       □No        □I Don’t Know  
Other symptoms: 
 
 
  
“Subjetive Date”:  
 
_______/________/_____________ 
 
Acute Case Date  
(from Case Report, Form 
A): _____/_____/________ 
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Occupation 
What is your current job/occupation at ISA? 
□ The same as above → MOVE TO SECTION 4* 
□ Hauler/loader 
□ Shrimp farm worker 
□ Pest control 
□ Weed control 
□ Sugarcane cutting, mechanical 
□ Sugarcane cutting, manual 
□ Seed cutting 
□ Factory 
□ General Crop Operator 
□ Fertilizer Operator 
□ Oven Operator 
□ Sugarcane burning 
□ Sowing/Reseeding 
□ Irrigation/Drainage 
□ Auto mechanic 
□ Other: ____________________________ 
What is the schedule that you normally worked?  
□ 6am     □ 7am       □ 8am       □ 9am       □ 10am       □ 11am       □ 12md    □ 1pm     □ 2pm    □ 3pm   
□ 4pm    □ 5pm     
□ 6pm     □ 7pm       □ 8pm       □ 9pm       □ 10pm       □ 11pm       □ 12mn    □ 1am     □ 2am    □ 3am   
□ 4am    □ 5am  
If you work shift, the second shift:  
□ 6am     □ 7am       □ 8am       □ 9am       □ 10am       □ 11am       □ 12md    □ 1pm     □ 2pm    □ 3pm   
□ 4pm    □ 5pm     
□ 6pm     □ 7pm       □ 8pm       □ 9pm       □ 10pm       □ 11pm       □ 12mn    □ 1am     □ 2am    □ 3am   
□ 4am    □ 5am 
How many days a week?     □ ≤3 days     □ 4 days       □ 5 days       □ 6 days       □ 7 days  □ other 
____________ 
Which months did you work during this season?  
 □ Jan       □ Feb       □ Mar       □ April        □ May       □ Jun       □ Jul         □ Aug       □ Sep       □ Oct     
□ Nov       □ Dec        
Did your work imply that you are working on water contact (standing or digging in water)?  □Yes    □No     □I 
Don’t Know 
 If your answer is Yes: What type of water? (Check all that apply)  
   □Irrigation      □Drainage      □Water source        □Rain          □Wet floor     
   □Standing water        □Shrimp water   □Other: 
____________________ 
Did your work imply that you are working in contact with soil? (ex. contact with skin or respiration) □Yes    
□No     □I Don’t Know 
 If your answer is Yes: What type of soil? (Check all that apply)  
   □Dry soil      □Wet soil      □Field soil       □Drainage soil      □Aerosolized 
soil 
   □Ground on the Road           □Other: ____________________ 
Did your work imply that you are working in contact with the burned cane?    □Yes    □No     □I Don’t Know 
 If your answer is Yes: What type of contact? (Check all that apply)  
   □Burning the sugar cane      □ Pick up the burnt cane      □Oven work         
   □Loading the burned sugar cane               □Other: ____________________ 
Did your work imply that you are working in contact with chemicals? □Yes    □No     □I 
Don’t Know  
 If your answer is Yes: What type of chemicals? (Check all that apply) 
    □Pesticide     □Herbicide       □Fertilizer         □Factory chemicals 
    □Other: ______________ 
  Do you know specifically which chemical(s)? 
_____________________________________________ 
  What type of contact? (Check all that apply) 
    □Applied □Fabric  □Skin contact  □Ingestion 
   □Inhalation □Into the eyes □Other: _____________________  
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Which of the following do you use when you are working? 
Gloves □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Glasses or sunglasses □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Mouth cover (mask) □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Nose cap □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Long pants □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Long sleeved shirt □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Boots □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Waterproof boots □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
Hat or cap □Yes, Always         □Usually        □Rarely □ No, Never □I Don’t Know 
 
Are you working any other jobs at the moment? (ex. peanuts, plantains, extraction or other jobs)  □Yes       □ 
No       □I don’t know           
If the answer is Yes:  Describe all other jobs _______________________ 
 
2. Work History 
 
What have been your other jobs/occupations in your work life? 
Activity Location (Country, 
Department) 
Start Year Number of Years 
□ Laborer    
□ Merchant    
□ Farmer    
□ Rancher    
□ Miner    
□ Ship worker    
□ Brick manufacturer    
□ Technical worker    
□ Other(s): 
 
 
   
 
What agricultural activities have you done in your life? 
Activity Location (Country, 
Department) 
Start Year Number of Years 
□ Rice    
□ Sesame    
□ Sugar    
□ Peanut    
□ Banana    
□ Corn    
□ Coffee    
□ Beans    
□ Vegetables    
□ Other(s): 
 
 
   
 
What position do you take part in that plant? 
Activity Start Year Number of Years 
□ Haulage   
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□ Shrimp farmer   
□ Pest control   
□ Weed control   
□ Sugar cane cutter, mechanical   
□ Sugar cane cutter, manual   
□ General Crop Operator   
□ Fertilizer Operator   
□ Oven Operator   
□ Burn the cane   
□ Sowing/Reseeding   
□ Irrigation/Drainage   
□ Auto mechanic   
□ Other(s): 
 
 
  
 
SECTION 4: 
Do you have any family members, now or in the past, with kidney disease, such as father, mother, 
brother, or uncle?  
□Yes □No □I Don’t Know  
Relation Age when 
you became 
sick 
Sex Occupation 
when you 
became sick 
Was it ever in 
agriculture? 
Did you ever work at ISA?  
If the answer is Yes,  
What work and for how long? 
How is he/she 
doing? 
(Ex. 
death/dialysis) 
    □Yes  □No  □I Don’t 
Know 
□Yes  □No  □I Don’t Know  
    □Yes  □No  □I Don’t 
Know 
□Yes  □No  □I Don’t Know  
    □Yes  □No  □I Don’t 
Know 
□Yes  □No  □I Don’t Know  
    □Yes  □No  □I Don’t 
Know 
□Yes  □No  □I Don’t Know  
What do you think is causing kidney disease in your community? 
 
What is the last level of the school that you completed? 
    □Primary  → Grade:_______ 
□Secondary → Grade:_______ 
□Superior → Technical school?  □Yes  □No  
□I Don’t Know 
□University→  Bachelor’s?   □Yes  □No  □I Don’t 
Know 
□None  
 
What is your marital status? 
   □Single         □Married         □In a relationship        □Widowed        
□Divorced 
□Other: _________________________ 
Where do you live currently? 
 Address: ___________________________________________  
Neighborhood/Region:___________________ 
 Municipality: ___________________________ Department:___________________________  
Do you work in the field/garden/farm where you currently live? □Yes   □No   □I Don’t Know   
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If the answer is Yes: Have you ever seen rats or mice while working there?     □Yes   □No   □I 
Don’t Know 
 
 
¿ Where did you live when you got sick in       ? 
□ The same house where I currently live 
 □ Other house:   
If it is a different house:  
  Address: ___________________________________________  
Neighborhood/Region:___________________ 
  Municipality: ___________________________ 
Department:___________________________  
 □Rural  □Urban  □Peri-urban  □I don’t know   
Did you work in the field/garden/farm where you lived?   □Yes   □No   □I Don’t Know 
If the answer is Yes: Have you ever seen rats or mice while working there?        □Yes   
□No   □I Don’t Know 
*If Subjective Date = Acute Case Date →MOVE on to the END* 
 
 
¿Where did you live when you got sick in         ? 
□ The same house where I currently live 
□ The same house where I lived when I became ill on acute case date (above) 
□ Another house:   
If the house is different:  
  Address: ___________________________________________  
Neighborhood/Region:___________________ 
  Municipality: ___________________________ 
Department:___________________________ 
 □Rural  □Urban  □Peri-urban  □ I don’t know   
Did you work in the field/garden/farm where you lived?   □Yes   □No   □I Don’t Know 
If the answer is Yes: Have you ever seen rats or mice while working   
“Subjective Date”: 
(from page 4):  
_______/________/______
_______ 
 
 
Acute Case Date  
(from Case Report, Form 
A): _____/_____/________ 
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